REVIEW The relevance of gender in Parkinson’s disease : a review Marina Picillo 1 • Alessandra Nicoletti 2 • Vincenza Fetoni 3 • Barbara Garavaglia 4 • Paolo Barone 1 • Maria Teresa Pellecchia 1 Received : 28 November 2016 / Revised : 21 December 2016 / Accepted : 22 December 2016 / Published online : 4 January 2017 (cid:2) Springer - Verlag Berlin Heidelberg 2016 Abstract Since the ofﬁcial and systematic inclusion of sex and gender in biomedical research , gender differences have been acknowledged as important determinants of both the susceptibility to develop neurodegenerative diseases in general population and the clinical and therapeutic man - agement of neurodegenerative patients . In this review , we gathered the available evidence on gender differences in Parkinson’s disease ( PD ) regarding clinical phenotype ( including motor and non - motor symptoms ) , biomarkers , genetics and therapeutic management ( including pharma - cological and surgical treatment ) . Finally , we will brieﬂy discuss the role of estrogens in determining such differ - ences . Several data demonstrate that PD in women starts with a more benign phenotype , likely due to the effect of estrogens . However , as the disease progresses , women are at higher risk of developing highly disabling treatment - related complications , such as motor and non - motor ﬂuc - tuations as well as dyskinesia , compared with men . In addition , women have lower chances of receiving effective treatment for PD as deep brain stimulation . Taken together these ﬁndings challenge the deﬁnition of a more benign phenotype in women . Still , much work needs to be done to better understand the interaction between gender , genetics and environmental factors in determining the PD risk and clinical features . Improving our understanding in this ﬁeld may result in implementation of strategies to identify prodromal PD and speed efforts to discern new directions for disease tailored treatment and management . Keywords Parkinson (cid:2) Gender (cid:2) Motor (cid:2) Non - motor (cid:2) Genetic (cid:2) Sex (cid:2) Treatment (cid:2) Surgery (cid:2) Biomarker Abbreviations AUC Area under the curve F Female M Male LEDD Levodopa equivalent daily dose NMS Non motor symptoms PD Parkinson’s disease UPDRS - III Uniﬁed Parkinson’s Disease Rating Scale part III Introduction According to the working deﬁnitions of sex and gender provided by the Institute of Medicine’s Committee on Understanding the Biology of sex and gender differences , the term sex refers to the classiﬁcation of living things , generally as male or female according to their reproductive organs and functions assigned by chromosomal comple - ment , while the term gender refers to a person’s self - rep - resentation as male or female , or how that person is responded to by social institutions based on the individ - ual’s gender presentation [ 1 ] . However , these terms are not univocal and cannot always be used in a mutually exclusive fashion . Thus , since gender is rooted in biology and shaped & Marina Picillo picillo . marina @ gmail . com 1 Center for Neurodegenerative Diseases ( CEMAND ) , Department of Medicine and Surgery , Neuroscience Section , University of Salerno , Salerno 84131 , Italy 2 Section of Neurosciences , Department GF Ingrassia , University of Catania , Catania , Italy 3 Neurologia Fatebenefratelli - ASST Fatebenefratelli Sacco , Milan , Italy 4 Molecular Neurogenetics Unit , IRCCS Foundation Neurological Institute ‘‘Carlo Besta’’ , Milan , Italy 123 J Neurol ( 2017 ) 264 : 1583 – 1607 DOI 10 . 1007 / s00415 - 016 - 8384 - 9 by environment and experience [ 1 ] , gender rather than sex is more appropriate to deﬁne the interaction of biological and social elements affecting health outcomes [ 1 ] . Sex differences in brain structure and function initiate through sex determining genes and fetal hormonal pro - gramming and have important implications for brain - based disease risk ; then , sex - speciﬁc genetic and hormonal fac - tors , as well as age - related physical changes further con - tribute to biological differences in expression of neurodegenerative diseases , including Parkinson’s disease ( PD ) [ 1 ] . In addition , a variety of broader societal factors , including role expectations and social attitudes , also have roles in the risk , course and outcome of neurodegenerative diseases . As a matter of fact , a range of behavioral and lifestyle choices associate with gender differences , including diet , exercise , smoking and caffeine are emerg - ing as potential modiﬁers of the PD risk during life [ 2 ] . Since the ofﬁcial and systematic inclusion of sex and gender in biomedical research [ 3 ] , gender differences have been acknowledged as important determinants of both the susceptibility to develop neurodegenerative diseases in general population and the clinical and therapeutic man - agement of neurodegenerative patients [ 4 ] . The aim of this review is to gather the available evi - dence on gender differences in PD regarding clinical phe - notype ( including motor and non - motor symptoms ) , biomarkers , genetics and therapeutic management ( in - cluding pharmacological and surgical treatment ) . Before the closedown , we will brieﬂy discuss the role of estrogens in determining such differences . However , since our approach is mainly clinical , we will not include in the present review all the preclinical data available on the topic . Indeed , improving our understanding in this ﬁeld may result in implementation of strategies to identify prodromal PD cases and speed efforts to discern new directions for PD tailored treatment and management . Methods The authors searched personal ﬁles and PubMed for peer - reviewed articles published in English language with no time limits . The search terms ‘‘agonist’’ , ‘‘biomarker’’ , ‘‘deep brain stimulation’’ , ‘‘epidemiology’’ , ‘‘gender’’ , ‘‘genetic’’ , ‘‘kinetic’’ , ‘‘levodopa’’ , ‘‘men’’ , ‘‘motor fea - tures’’ , ‘‘non - motor features’’ , ‘‘Parkinson’’ , ‘‘sex’’ , ‘‘sur - gery’’ , ‘‘weight’’ and ‘‘women’’ were used . Additional articles were identiﬁed by searching the reference lists of identiﬁed reviews that provided insightful or comprehen - sive overviews on gender differences in PD . The studies and meta - analysis considered in this review are detailed in Table 1 . Epidemiology and phenotypic differences Epidemiology Conﬁrming previous data [ 5 ] , a meta - analysis including 17 relevant studies and over 2500 PD cases , determined an overall age - standardized incidence M : F ratio of 1 . 46 ( 95 % CI 1 . 24 – 1 . 72 ) [ 6 ] . This meta - analysis also disclosed a high - level heterogeneity between included studies and a positive relationship between age of onset and M : F incidence ratio [ 6 , 7 ] . As for prevalence , a meta - analysis including data published between 1985 and 2000 reported a signiﬁcant difference in gender ratio for individuals from 50 to 59 years old , with a PD prevalence of 41 / 100 . 000 in women and 134 / 100 . 000 in men ( p \ 0 . 05 ) [ 8 ] . When stratiﬁed by geographic location , M : F prevalence ratios were in favour of men in both the Western countries and South America , but not in Asia , although methodological issues may account for such discrepancy [ 8 ] . By analyzing the Health Insurance drugs reimbursement databases , a recent French nationwide study largely con - ﬁrmed previous data reporting an overall M : F incidence ratio of 1 . 49 ( 95 % CI 1 . 41 – 1 . 57 , p \ 0 . 001 ) and an overall M : F prevalence ratio of 1 . 48 ( 95 % CI 1 . 45 – 1 . 51 , p \ 0 . 001 ) [ 9 ] . Both M : F incidence and prevalence ratios were markedly inﬂuenced by age in a strikingly progres - sive pattern , with incidence increasing by 0 . 14 per 10 - year age increment and prevalence increasing by 0 . 05 for every 10 - year age increment . As expected , this pattern was more pronounced for incidence than prevalence ratios , since the latter is most likely affected by gender differences in sur - vival [ 9 ] . Indeed , male sex is associated with an increased mortality rate in PD for two complementary reasons [ 10 – 12 ] . First , it is the reﬂexion of the overall shorter life expectancy of men in the general population . Then , the factors usually predicting higher mortality in PD , as cog - nitive impairment and higher postural instability and gait scores , are much more common in men [ 10 – 12 ] . Motor symptoms By examining a clinic - based cohort of 253 subjects , Haaxma et al . ﬁrst delineated phenotypic gender differ - ences in a large sample of PD patients [ 13 ] . Key ﬁndings of this study were : ( a ) women were 2 years older than men at symptom onset and presented more likely with tremor ( 67 % ) than men ( 48 % ) ; ( b ) tremor dominance was asso - ciated with a slower decline on motor scales ; ( c ) at symptoms onset , women had 16 % higher striatal [ 123I ] FP - CIT binding than men ; ( d ) in women , age at onset corre - lated positively with parity , age at menopause and fertile life span [ 13 ] . Taken together , these ﬁndings suggest a more benign phenotype in women with PD possibly related 1584 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 S t ud i e s a nd m e t a - a n a l y s e s f o c u s e d on g e nd e r d i ff e r e n ce s i n P a r k i n s on ’ s d i s ea s e i n c l ud e d i n t h e r e v i e w S t udy T yp e o f s t udy A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s E p i d e m i o l ogy L onn e k e [ 10 ] 5 - y ea r p r o s p ec ti v e , ho s p it a l - b a s e d s t udy ( p a r t o f t h e P R O P A R K c oho r t , t h e N e t h e r l a nd s ) T o i d e n ti f y m o t o r a nd non - m o t o r f ea t u r e s p r e d i c ti ng m o r t a lit y i n P D 414 ( 64 ) 61 . 14 ( 11 . 37 ) 10 . 62 ( 6 . 5 3 ) 49 ( 11 . 8 % ) p a ti e n t s d i e d M a l e s e x , o l d e r a g e a nd h i gh e r P I GD s c o r e , c ogn iti v e i m p a i r m e n t a nd p s y c ho ti c s y m p t o m s p r e d i c t e d d ec r ea s e d s u r v i v a l M o i s a n [ 9 ] F r e n c h n a ti on w i d e s t udy b a s e d on n a ti on a l d r ug s d a t a b a s e s ( F r e n c h N a ti on a l H ea lt h I n s u r a n ce ) T o i nv e s ti g a t e s e x d i ff e r e n ce s i n P D fr e qu e n c y a nd c ondu c t a m e t a - a n a l y s i s o f t h e a v a il a b l e lit e r a t u r e 188 . 562 ( NA ) NA NA M : F r a ti o s w e r e 1 . 48 ( 95 % C I 1 . 45 – 1 . 51 , p \ 0 . 001 ) f o r p r e v a l e n ce a nd 1 . 49 ( 95 % C I 1 . 41 – 1 . 57 , p \ 0 . 001 ) f o r i n c i d e n ce M : F i n c i d e n ce a nd p r e v a l e n ce r a ti o s i n c r ea s e d w it h a g e , w it h i n c i d e n ce i n c r ea s i ng by 0 . 14 p e r 10 - y ea r a g e i n c r e m e n t a nd p r e v a l e n ce i n c r ea s i ng by 0 . 05 f o r e v e r y 10 - y ea r a g e i n c r e m e n t T h e m e t a - a n a l y s i s i n c l ud i ng 22 i n c i d e n ce s t ud i e s ( 14 . 126 ca s e s , 46 % w o m e n ) c on ﬁ r m e d t h a t M : F r a ti o s i n c r ea s e w it h a g e ( 0 . 26 p e r 10 y ea r s , p = 0 . 005 ) P i n t e r [ 11 ] 38 - y ea r p r o s p ec ti v e s t udy ( A u s t r i a ) T o i d e n ti f y p r e d i c t o r s o f m o r t a lit y i n P D 237 ( NA ) NA NA 230 ( 97 % ) p a ti e n t s d i e d M a l e s e x , g a it d i s o r d e r s a nd a b s e n ce o f t r e m o r o r un e qu i vo ca l a s y mm e t r y a t on s e t p r e d i c t e d m o r t a lit y P r i ng s h e i m [ 8 ] M e t a - a n a l y s i s i n c l ud i ng 47 doo r - t o - doo r o r popu l a ti on - b a s e d p r e v a l e n ce s t ud i e s S y s t e m a ti c r e v i e w o f P D p r e v a l e n ce s t u d i e s w o r l d w i d e 2 . 019 P D ou t o f 4 . 665 . 742 o f s ub j ec t s c on s i d e r e d NA NA P D p r e v a l e n ce r i s e s w it h a g e M a l e p r e do m i n a n ce i s p r e s e n t i n a ll a g e g r oup s bu t i s s i gn i ﬁ ca n t i n t h e 50 - 59 a g e g r oup ( F = 41 / 100 . 000 ; M = 134 / 100 . 000 ) M : F p r e v a l e n ce r a ti o s w e r e i n f a vou r o f m e n i n bo t h t h e W e s t e r n c oun t r i e s a nd S ou t h A m e r i ca , bu t no t i n A s i a T a y l o r [ 6 ] M e t a - a n a l y s i s i n c l ud i ng 14 s t ud i e s S y s t e m a ti c r e v i e w o f P D i n c i d e n ce s t ud i e s 2 . 557 ( NA ) 70 . 6 NA I n c i d e n ce M : F r a ti o o f 1 . 46 ( 95 % C I 1 . 24 – 1 . 72 ) W oo t e n [ 5 ] M e t a - a n a l y s i s i n c l ud i ng 7 s t ud i e s T o r e v i e w t h e g e nd e r d i ff e r e n ce s i n P D i n c i d e n ce s t ud i e s 1 . 837 ( 51 . 95 ) NA NA M : F w e i gh t e d m ea n i n c i d e n ce = 1 . 49 X u [ 12 ] M e t a - a n a l y s i s i n c l ud i ng 8 s t ud i e s T o e v a l u a t e m o r t a lit y r i s k a nd p r e d i c t o r s i n P D 718 P D d ea t h s a nd 13 . 660 h ea lt hy c on t r o l s ( H C ) d ea t h s NA NA P D h a d a g r ea t e r r i s k o f a ll - ca u s e m o r t a lit y ( RR = 2 . 22 ; 95 % C I 1 . 78 – 2 . 77 ) P D p a ti e n t s w it h d e m e n ti a h a d h i gh e r m o r t a lit y r i s k ( RR = 3 . 78 ; 95 % C I 2 . 06 – 6 . 92 ) M a l e g e nd e r w a s a ss o c i a t e d w it h h i gh e r m o r t a lit y r a t e s ( RR = 2 . 05 ; 95 % C I 1 . 36 – 3 . 08 ) S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s M o t o r s y m p t o m s B j o r n e s t a d [ 18 ] 5 - y ea r p r o s p ec ti v e , l ong it ud i n a l popu l a ti on - b a s e d s t udy ( M u lti ce n t e r , N o r w a y ) T o d e t e r m i n e t h e i n c i d e n ce , r i s k f ac t o r s , e vo l u ti on , a nd t r ea t m e n t o f m o t o r ﬂ u c t u a ti on s a nd dy s k i n e s i a s 189 ( 60 . 3 ) 67 . 7 ( 9 . 3 ) 2 . 3 ( 9 . 3 ) T h e 5 - y ea r c u m u l a ti v e i n c i d e n ce o f m o t o r c o m p li ca ti on s w a s 52 . 4 % M o t o r ﬂ u c t u a ti on s o cc u rr e d i n 42 . 9 % a nd l e vodop a - i ndu ce d dy s k i n e s i a s ( L I D ) i n 24 . 3 % S e v e r e r m o t o r s c o r e s p r e d i c t e d bo t h m o t o r ﬂ u c t u a ti on s ( p = 0 . 016 ) a nd L I D ( p \ 0 . 001 ) , l o w e r a g e a t d i a gno s i s p r e d i c t e d m o t o r ﬂ u c t u a ti on s ( p = 0 . 001 ) , w h e r ea s f e m a l e g e nd e r p r e d i c t e d L I D ( p = 0 . 001 ) i rr e s p ec ti v e t o body w e i gh t J Neurol ( 2017 ) 264 : 1583 – 1607 1585 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s C e r e d a [ 14 ] C r o ss - s ec ti on a l s t udy ( I t a l y ) T o i nv e s ti g a t e t h e po t e n ti a l e ff ec t o f r e p r odu c ti v e f ac t o r s on t h e c li n i ca l f ea t u r e s o f P D 579 ( 0 ) 68 . 5 ( 9 . 9 ) 5 ( r a ng e 2 – 9 ) A g e a t P D on s e t w a s po s iti v e l y a ss o c i a t e d w it h a g e a t m e n a r c h e a nd a t m e nop a u s e , l e ng t h o f f e r til e li f e a nd du r a ti on o f e s t r og e n e xpo s u r e U P D R S m o t o r s c o r e w a s i nv e r s e l y a ss o c i a t e d w it h a g e a t m e nop a u s e , l e ng t h o f f e r til e li f e a nd du r a ti on o f e s t r og e n e xpo s u r e I n c r ea s i ng a g e a t m e n a r c h e w a s a l s o a ss o c i a t e d w it h p r e do m i n a n t r e s ti ng t r e m o r a t P D on s e t C o l o m bo [ 19 ] C r o ss - s ec ti on a l s t udy ( M u lti ce n t e r , I t a l y ) T o e v a l u a t e g e nd e r d i ff e r e n ce s i n w ea r i ng o ff 617 ( 61 . 8 ) 66 . 8 ( 9 . 2 ) \ 5 y ea r s : 185 [ 5 y ea r s : 432 P r e v a l e n ce o f w ea r i ng o ff w a s h i gh e r a m ong w o m e n , acc o r d i ng t o bo t h n e u r o l og i s t s ’ j udg m e n t a nd t h e W OQ - 19 H aa x m a [ 13 ] L ong it ud i n a l , p r o s p ec ti v e s t udy ( t h e N e t h e r l a nd s ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n d i s ea s e c h a r ac t e r i s ti c s , m o t o r d e t e r i o r a ti on a nd n i g r o s t r i a t a l d e g e n e r a ti on 253 ( 62 ) 53 . 7 ( r a ng e 28 – 79 ) 2 . 6 ( r a ng e 2 – 10 ) A g e a t on s e t w a s 2 . 1 y ea r s l a t e r i n w o m e n ( 53 . 4 y ea r s ) t h a n i n m e n ( 51 . 3 y ea r s ) I n w o m e n , a g e a t on s e t c o rr e l a t e d po s iti v e l y w it h p a r it y , a g e a t m e nop a u s e a nd f e r til e li f e s p a n W o m e n p r e s e n t e d m o r e o f t e n w it h t r e m o r ( 67 % ) t h a n m e n ( 48 % ) O v e r a ll , p a ti e n t s p r e s e n ti ng w it h t r e m o r h a d a 3 . 6 y ea r h i gh e r a g e a t on s e t a nd a 38 % s l o w e r U P D R S - III d e t e r i o r a ti on W o m e n h a d a 16 % h i gh e r s t r i a t a l [ 123 I ] FP - C I T b i nd i ng t h a n m e n a t s y m p t o m on s e t a nd t h r oughou t t h e c ou r s e o f P D H a ss i n - B ae r [ 22 ] H i s t o r i ca l p r o s p ec ti v e s t udy ( I s r ae l ) T o i d e n t i f y f ac t o r s a ss o c i a t e d w it h ti m e t o a pp ea r a n ce o f l e vodop a - i ndu ce d dy s k i n e s i a 155 ( 58 . 1 ) NA NA P a ti e n t s w it h L I D ( 57 . 4 % ) w e r e s i gn i ﬁ ca n tl y young e r a t d i s ea s e on s e t t h a n t ho s e w it hou t F e m a l e g e nd e r w a s a ss o c i a t e d w it h a s ho r t e r ti m e t o L I D a nd t h e m e d i a n ti m e t o L I D w a s 6 y ea r s f o r m a l e s a nd 4 y ea r s f o r f e m a l e s ( p = 0 . 004 ) S a t o [ 17 ] R e t r o s p ec ti v e s t udy ( J a p a n ) T o r e po r t l ong - t e r m ou t c o m e s o f P D J a p a n e s e p a ti e n t s 1 . 768 ( 44 . 8 ) 66 . 1 ( 10 . 1 ) 9 . 4 ( 6 . 2 ) T i m e t o r eac h H & Y = III w a s s li gh tl y bu t s i gn i ﬁ ca n tl y s ho r t e r i n w o m e n ( p \ 0 . 001 ) T i m e t o d e v e l op w ea r i ng o ff a nd L I D w a s s ho r t e r i n w o m e n c o m p a r e d t o m e n S a und e r s - P u ll m a n [ 16 ] R e t r o s p ec ti v e s t udy ( U S A ) T o d e t e r m i n e w h e t h e r t h e r e a r e g e nd e r d i s c r e p a n c i e s i n d i a gn o s i s a nd ti m e t o p r e s e n t t o a m ov e m e n t d i s o r d e r s p ec i a l i s t 109 ( 51 . 3 ) 63 . 5 ( r a ng e 54 . 9 – 70 ) 1 . 9 ( r a ng e 1 . 1 – 4 . 1 ) T h e e xp ec t e d du r a ti on fr o m on s e t t o m ov e m e n t d i s o r d e r s p ec i a li s t v i s it f o r w o m e n w a s 61 % g r ea t e r t h a n f o r m e n i n t h e un a d j u s t e d m od e l ( p = 0 . 002 ) 1586 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s Z a pp i a [ 20 ] C oho r t s t udy ( I t a l y ) T o e x a m i n e c li n i ca l a nd g e n e ti c r i s k f ac t o r s f o r i nd i v i du a l s u s ce p ti b ilit y o f p ea k - do s e dy s k i n e s i a 215 ( 57 . 2 ) 66 . 6 ( 8 . 6 ) 8 . 7 ( 5 ) 115 p a ti e n t s ( 48 . 8 % ) e xh i b it e d p ea k - do s e dy s k i n e s i a f o ll o w i ng s ho r t - t e r m l e vodop a a d m i n i s t r a ti on , a nd 110 p a ti e n t s ( 51 . 2 % ) d i d no t I n t h e w ho l e s a m p l e p r e d i c t o r s f o r t h e o cc u rr e n ce o f L I D w e r e : f e m a l e s e x ( O R 3 . 29 ; 95 % C I 1 . 76 – 6 . 17 ) , ea r li e r a g e a t on s e t ( O R 1 . 05 ; 95 % C I 1 . 02 – 1 . 09 ) du r a ti on o f L D t r ea t m e n t ( O R 1 . 1 ; 95 % C I 1 . 02 – 1 . 19 ) L D do s a g e ( O R 1 . 001 ; 95 % C I 1 – 1 . 003 ) I n m e n p r e d i c t o r s f o r t h e o cc u rr e n ce o f L I D w e r e : ea r li e r a g e a t on s e t ( O R 1 . 08 ; 95 % C I 1 . 03 – 1 . 13 ) , L D do s a g e ( O R 1 . 002 ; 95 % C I 1 – 1 . 003 ) , C A n S T R g e no t yp e ( O R 0 . 34 ; 95 % C I 0 . 14 – 0 . 84 ) a nd body w e i gh t \ 61 kg ( O R 7 . 64 ; 95 % C I 1 . 36 – 42 . 92 ) I n f e m a l e on l y ea r li e r a g e a t on s e t w a s b e s t p r e d i c t o r t h e o cc u rr e n ce o f p ea k - do s e dy s k i n e s i a ( O R 1 . 07 ; 95 % C I 1 . 02 – 1 . 13 ; p = 0 . 008 ) N on - m o t o r s y m p t o m s A n a ng [ 39 ] P r o s p ec ti v e c oho r t s t udy ( C a n a d a ) T o i nv e s ti g a t e a s e t o f po ss i b l e m a r k e r s o f ea r l y d e m e n ti a i n P D 80 ( 63 . 7 ) 66 . 2 ( 10 . 9 ) 5 . 7 ( 4 . 2 ) 27 / 80 ( 34 % ) d e v e l op e d d e m e n ti a P r e d i c t o r s o f d e m e n ti a w e r e : m a l e g e nd e r ( O R = 3 . 64 , p = 0 . 023 ) , b a s e li n e m il d c ogn iti v e i m p a i r m e n t ( O R = 22 . 5 , p = 0 . 001 ) , RB D ( O R = 49 . 7 , p = 0 . 001 ) ; h i gh e r b a s e li n e b l ood p r e ss u r e ( O R = 1 . 37 p e r 10 mm H g , p = 0 . 032 ) , o r t ho s t a ti c b l ood p r e ss u r e d r op ( O R = 1 . 84 p e r 10 mm H g , p = 0 . 001 ) ; a bno r m a l c o l o r v i s i on ( O R = 3 . 3 , p = 0 . 014 ) A ugu s ti n e [ 129 ] C r o ss - s ec ti on a l a n a l y s i s o f a m u lti ce n t e r c li n i ca l t r i a l ( N ET - P D ) T o e x a m i n e g e nd e r d i ff e r e n ce s i n c li n i ca l f ea t u r e s a nd d i s ea s e s e v e r it y 1 . 741 ( 62 . 5 ) R a ng e 30 – 80 1 . 7 ( 1 . 8 ) W o m e n h a d b e tt e r p e rf o r m a n ce c o m p a r e d t o m e n on t h e S C O P A - C OG ( p \ 0 . 0001 ) a nd t h e S y m bo l D i g it M od a lit y m ea s u r e s ( p \ 0 . 0001 ) C e r e d a , 2016 [ 4 1 ] C r o ss - s ec ti on a l , r e t r o s p ec ti v e s t udy ( I t a l y ) T o i nv e s ti g a t e t h e r e l a ti on s h i p b e t w ee n d e m e n ti a a nd g e nd e r a l ong w it h o t h e r r i s k f ac t o r s , s u c h a s a g e a nd d i s ea s e du r a ti on 6 . 599 ( 58 . 3 ) 68 . 4 ( 10 . 1 ) 8 . 6 ( 6 . 4 ) P r e v a l e n ce o f d e m e n ti a w a s 11 . 5 % ( 95 % C I 10 . 8 – 12 . 3 ) A g e , d i s ea s e du r a ti on a nd m a l e g e nd e r i nd e p e nd e n tl y p r e d i c t e d d e m e n ti a W h il e t h e r a t e o f d e m e n ti a i n c r ea s e d i n m a l e s ov e r a ll a g e s t r a t a , f e m a l e s p r e v a l e n ce b e g a n t o i n c r ea s e s t ea d il y a f t e r t h e a g e o f 65 y ea r s , r eac h i ng m a l e e s ti m a t e s on l y a f t e r 80 y ea r s o f a g e F e ng l e r [ 130 ] C r o ss - s ec ti on a l , r e t r o s p ec ti v e s t udy ( M u lti ce n t e r , G e r m a ny ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n c ogn iti v e t e s t s 656 ( 67 . 8 ) 67 . 5 ( 7 . 8 ) 6 . 8 ( 5 . 4 ) R a w - s c o r e a n a l y s i s s ho w e d t h a t P D w o m e n s c o r e d h i gh e r i n v e r b a l m e m o r y ( w o r d li s t l ea r n i ng , p = 0 . 02 ; r eca ll , p = 0 . 03 ) , w h il e m e n ou t p e rf o r m e d w o m e n i n v i s uo c on s t r u c ti on ( p = 0 . 002 ) a nd t e s t s e v a l u a ti ng r eca ll o f ﬁ gu r e s ( p = 0 . 005 ) G e nd e r - c o rr ec t e d Z s c o r e s s ho w e d t h a t m e n s c o r e d h i gh e r i n v e r b a l m e m o r y ( w o r d li s t l ea r n i ng , p = 0 . 02 ; r eca ll , p = 0 . 02 ; r ec ogn iti on , p = 0 . 04 ) , w h il e no d i ff e r e n ce w a s f ound f o r v i s uo s p a ti a l t e s t s J Neurol ( 2017 ) 264 : 1583 – 1607 1587 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s G a o [ 131 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n c ogn iti v e p e rf o r m a n ce s 311 ( 55 . 3 ) 60 . 8 ( 11 . 3 ) 3 . 8 ( 5 ) M on t r ea l C ogn iti v e A ss e ss m e n t ( M o C A ) s c o r e s w e r e h i gh e r i n m e n ( p \ 0 . 05 ) M e n h a d b e tt e r p e rf o r m a n ce s i n v i s uo s p a ti a l f un c ti on , n a m i ng a nd a b s t r ac ti on ( p \ 0 . 05 ) W o m e n h a d l o w e r s c o r e s i n i n f o r m a ti on , vo ca bu l a r y , p i c t u r e c o m p l e ti on , b l o c k d e s i gn a nd p i c t u r e a rr a ng e m e n t ( p \ 0 . 05 ) G uo [ 36 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o e v a l u a t e g e nd e r - a nd a g e - r e l a t e d d i ff e r e n ce s i n non - m o t o r s y m p t o m s i n C h i n e s e p a ti e n t s 522 ( 56 . 7 ) 61 . 6 ( 11 . 4 ) 4 . 4 ( 4 . 1 ) W o m e n h a d m o r e fr e qu e n tl y N M S i n s l ee p / f a ti gu e , m ood / a p a t hy do m a i n a nd p a i n s y m p t o m s M e n h a d m o r e fr e qu e n tl y u r i n a r y s y m p t o m s L ee n tj e n s [ 23 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o d e s c r i b e t h e fr e qu e n c y a nd s y m p t o m s a nx i e t y d i s o r d e r s , a s w e ll a s t o i d e n ti f y t h e i r r i s k f ac t o r s i n a P D popu l a ti on 340 ( 61 ) 64 . 8 ( 9 . 2 ) 8 . 2 ( 5 . 5 ) 34 % o f s ub j ec t s m e t t h e D S M - I V c r it e r i a f o r a t l ea s t on e a nx i e t y d i s o r d e r ; 11 . 8 % m e t c r it e r i a f o r m u lti p l e a nx i e t y d i s o r d e r s ; a nd 11 . 4 % h a d c li n i ca ll y r e l e v a n t a nx i e t y s y m p t o m s w it hou t m ee ti ng t h e c r it e r i a f o r a ny s p ec i ﬁ c a nx i e t y d i s o r d e r F e m a l e s e x , t h e p r e s e n ce o f m o t o r ﬂ u c t u a ti on s , a s w e ll a s a p r e v i ou s h i s t o r y o f a n a nx i e t y d i s o r d e r w e r e m a r k e r s f o r a nx i e t y d i s o r d e r s L ee n tj e n s [ 24 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o c on s t r u c t a m od e l f o r d e p r e ss i on i n P D a nd t o s t udy t h e r e l a ti v e c on t r i bu ti on o f P D - s p ec i ﬁ c a nd non s p ec i ﬁ c r i s k f ac t o r s t o t h i s m od e l 340 ( 61 % ) 64 . 8 ( 9 . 2 ) 8 . 3 ( 5 . 6 ) T h r ee P D - s p ec i ﬁ c v a r i a b l e s ( i n c r ea s e d d i s ea s e du r a ti on , m o r e s e v e r e m o t o r s y m p t o m s , t h e u s e o f l e vodop a ) a nd 6 non - s p ec i ﬁ c v a r i a b l e s ( f e m a l e s e x , h i s t o r y o f a nx i e t y a nd / o r d e p r e ss i on , f a m il y h i s t o r y o f d e p r e ss i on , w o r s e f un c ti on i ng on ac ti v iti e s o f d a il y li v i ng , a nd w o r s e c ogn iti v e s t a t u s ) w e r e s i gn i ﬁ ca n tl y a ss o c i a t e d w it h d e p r e ss i on N on - s p ec i ﬁ c r i s k f ac t o r s h a d a 3 - ti m e s h i gh e r i n ﬂ u e n ce i n t h e m od e l t h a n P D - s p ec i ﬁ c r i s k f ac t o r s L i u [ 34 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy - PP M I c oho r t ) T o e x a m i n e po t e n ti a l s e x d i ff e r e n ce s i n non - m o t o r s y m p t o m s , a nd t o i d e n ti f y s y m p t o m s t h a t ca n b e s t d i ff e r e n ti a t e p a ti e n t s w it h ea r l y P D fr o m H C P D : 414 ( 64 . 9 ) H C : 188 ( 64 . 3 ) P D : 62 . 1 ( 9 . 8 ) H C : 61 . 7 ( 10 . 9 ) 6 . 3 ( 6 ) m on t h s M a l e P D p a ti e n t s h a d m o r e p r onoun ce d d e ﬁ c it s i n o l f ac ti on ( p = 0 . 02 ) a nd i n ce r t a i n c ogn iti v e m ea s u r e m e n t s ( a ll p \ 0 . 01 ) t h a n f e m a l e p a ti e n t s F e m a l e P D p a ti e n t s e xp e r i e n ce d h i gh e r t r a it a nx i e t y ( p = 0 . 02 ) T h e c o m b i n a ti on o f t h e U n i v e r s it y o f P e nn s y l v a n i a S m e ll I d e n ti ﬁ ca ti on T e s t ( U PS I T ) , M o C A , S ca l e s f o r O u t c o m e s i n P a r k i n s on ’ s D i s ea s e – A u t ono m i c ( S C O P A - AU T ) , a nd s t a t e a nx i e t y fr o m t h e S t a t e - T r a it A nx i e t y I nv e n t o r y e ff ec ti v e l y d i ff e r e n ti a t e d p a ti e n t s w it h P D fr o m H C U PS I T , M o C A , a nd S C O P A - AU T p r e d i c t e d P D d i a gno s i s i n m e n U PS I T , M o C A , a nd RB D S c r ee n i ng Q u e s ti onn a i r e p r e d i c t e d P D d i a gno s i s i n w o m e n 1588 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s M a r ti n ez - M a r ti n [ 27 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o d e t e r m i n e t h e d i ff e r e n ce by g e nd e r i n t h e fr e qu e n c y a nd s e v e r it y o f a r a ng e o f non - m o t o r s y m p t o m s 951 ( 62 . 6 ) 64 . 4 ( 9 . 9 ) 7 . 9 ( 5 . 7 ) F a ti gu e , f ee li ng s o f n e r vou s n e ss , f ee li ng s o f s a dn e ss , c on s ti p a ti on , r e s tl e ss l e g s , a nd p a i n w e r e m o r e c o mm on a nd s e v e r e i n w o m e n D a y ti m e s l ee p i n e ss , d r i bb li ng s a li v a , i n t e r e s t i n s e x , a nd p r ob l e m s h a v i ng s e x w e r e m o r e p r e v a l e n t a nd s e v e r e i n m e n R e g a r d i ng t h e N M S do m a i n s , M ood / A p a t hy a nd M i s ce ll a n e ou s p r ob l e m s ( p a i n , l o ss o f t a s t e o r s m e ll , w e i gh t c h a ng e , a nd e x ce ss i v e s w ea ti ng ) w e r e p r e do m i n a n tl y a ff ec t e d i n w o m e n a nd s e xu a l dy s f un c ti on i n m e n N i c o l e tti [ 42 ] C a s e – c on t r o l , c r o ss - s ec ti on a l ( m u lti ce n t e r , I t a l y ) T o e v a l u a t e g e nd e r d i ff e r e n ce s i n N M S p r e v a l e n ce i n P D a n d i n c o m p a r i s on w it h H C P D : 585 ( 59 . 5 ) H C : 481 ( 34 . 9 ) P D : 66 . 8 ( 9 . 8 ) H C : 63 . 4 ( 10 . 1 ) 7 . 2 ( 5 . 6 ) A ll N M S w e r e m o r e fr e qu e n t i n P D t h a n H C ; P D w o m e n s ho w e d h i gh e r fr e qu e n c y o f d e p r e ss i on a nd u r i n a r y d i s t u r b a n ce s t h a n m e n W it h r e s p ec t t o t h e c on t r o l popu l a ti on , acc o r d i ng t o l og i s ti c r e g r e ss i on s t r a ti ﬁ e d by s e x a nd a d j u s t e d by a g e , P D m e n s ho w e d a s t r ong e r po s iti v e s i gn i ﬁ ca n t a ss o c i a ti on w it h a l m o s t a ll N M S c o m p a r e d t o w o m e n , e x ce p ti ng f o r u r i n a r y d i s t u r b a n ce s T h e s t r ong e s t a ss o c i a ti on a m ong P D m e n w a s r ec o r d e d f o r c ogn iti v e i m p a i r m e n t ( a d j u s t e d O R 5 . 44 f o r m e n a nd 2 . 82 f o r w o m e n ) a nd d e p r e ss i on ( a d j u s t e d O R 30 . 88 f o r m e n a nd 12 . 72 f o r w o m e n ) P i c ill o [ 29 ] C r o ss - s ec ti on a l s t udy ( I t a l y ) T o a ss e s s g e nd e r e ff ec t on t h e p r e v a l e n ce o f non - m o t o r s y m p t o m s i n a l a r g e c oho r t o f ea r l y , d r ug - n a ı ¨ v e P D p a ti e n t s c o m p a r e d w it h a g e a nd s e x - m a t c h e d H C P D : 200 ( 63 ) H C : 93 ( 64 . 5 ) P D : 61 . 3 ( 8 . 8 ) H C : 60 . 7 ( 7 . 8 ) 11 . 5 ( 9 . 5 ) m on t h s M a l e P D p a ti e n t s c o m p l a i n e d o f p r ob l e m s h a v i ng s e x a nd t a s t e / s m e lli ng d i f ﬁ c u lti e s s i gn i ﬁ ca n tl y m o r e fr e qu e n tl y t h a n f e m a l e P D p a ti e n t s M e n w it h P D c o m p l a i n e d m o r e fr e qu e n tl y o f d r i bb li ng , s a dn e ss / b l u e s , l o ss o f i n t e r e s t , a nx i e t y , ac ti ng du r i ng d r ea m s , a nd t a s t e / s m e lli ng d i f ﬁ c u lti e s c o m p a r e d t o H C m e n F e m a l e P D p a ti e n t s r e po r t e d m o r e fr e qu e n tl y l o ss o f i n t e r e s t a nd a nx i e t y a s c o m p a r e d w it h H C w o m e n P i c ill o [ 35 ] 2 - y ea r p r o s p ec ti v e s t udy ( I t a l y ) T o a ss e s s g e nd e r - r e l a t e d d i ff e r e n ce s i n non - m o t o r s y m p t o m s b e f o r e a nd a f t e r s t a r ti ng dop a m i n e r g i c t h e r a p y i n n e w l y d i a gno s e d P D p a ti e n t s 134 ( 64 . 2 ) 63 ( 8 . 6 ) 38 . 7 ( 11 . 3 ) m on t h s S a dn e ss / b l u e s p r e s e n t e d a s i gn i ﬁ ca n t p e r ce n t a g e r e du c ti on c o m p a r e d t o b a s e li n e i n bo t h s e x e s U r g e n c y , d a y ti m e s l ee p i n e ss , w e i gh t g a i n a nd s e x d r i v e p r e s e n t e d a s i gn i ﬁ ca n t p e r ce n t a g e i n c r ea s e on l y i n m e n O cc u rr e n ce o f w e i gh t g a i n w a s r e l a t e d t o t h e r a py i n bo t h s e x e s M a l e g e nd e r w a s a r i s k f ac t o r f o r d r i bb li ng a nd no c t u r i a , i rr e s p ec ti v e o f t h e r a py a nd c li n i ca l f ea t u r e s J Neurol ( 2017 ) 264 : 1583 – 1607 1589 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s P i c ill o [ 37 ] 4 - y ea r p r o s p ec ti v e s t udy ( I t a l y ) T o a ss e s s t h e r e l a ti on s h i p b e t w ee n non - m o t o r ﬂ u c t u a ti on s a nd g e nd e r a l ong w it h o t h e r po t e n ti a l r i s k f ac t o r s 47 ( 65 . 9 ) 60 . 7 ( 8 . 4 ) 14 ( 5 . 6 ) m on t h s F e m a l e g e nd e r w a s a ss o c i a t e d w it h non - m o t o r ﬂ u c t u a ti on s ( O R = 5 . 33 , 95 % C I 1 . 21 – 23 . 4 , p = 0 . 027 ) W o m e n h a d g r ea t e r li k e li hood o f d e v e l op i ng h i gh e r W OQ - 19 N on - m o t o r s c o r e s ( O R = 4 . 58 , 95 % C I 1 . 23 - 17 . 03 , p = 0 . 023 ) N o t w it h s t a nd i ng , no g e nd e r d i ff e r e n ce s w e r e d e t ec t e d i n m e d i ca ti on i n t a k e P i go tt [ 40 ] 6 - y ea r l ong it ud i n a l p r o s p ec ti v e s t udy ( U S A ) T o r e po r t t h e r a t e s a nd p r e d i c t o r s o f p r og r e ss i on fr o m no r m a l c ogn iti on t o e it h e r m il d c ogn iti v e i m p a i r m e n t o r d e m e n ti a 141 ( 63 ) 68 . 6 ( 7 ) 5 ( 4 . 4 ) T h e c u m u l a ti v e i n c i d e n ce o f c ogn iti v e i m p a i r m e n t w a s 8 . 5 % a t y ea r 1 a nd 47 . 4 % by y ea r 6 I n a m u lti v a r i a t e a n a l y s i s , p r e d i c t o r s o f f u t u r e d ec li n e w e r e m a l e s e x ( p = 0 . 02 ) , h i gh e r U P D R S m o t o r s c o r e ( p B 0 . 001 ) , a nd w o r s e g l ob a l c ogn iti v e s c o r e s ( p \ 0 . 001 ) S c o tt 2000 [ 132 ] P o s t a l s u r v e y ( S w e d e n ) T o e v a l u a t e g e nd e r d i ff e r e n ce s i n s y m p t o m s s e v e r it y a nd p r og r e ss i on 948 ( 62 . 2 ) 66 o r o l d e r 11 . 1 A t s y m p t o m on s e t , w o m e n r e po r t e d n ec k - p a i n a nd l o w b ac k p a i n m o r e fr e qu e n tl y t h a n m e n A t t h e ti m e o f t h e e v a l u a ti on , w r iti ng d i f ﬁ c u lti e s , f u m b li ngn e ss , g a it p r ob l e m s , s p eec h p r ob l e m s , i n c r ea s e d s a li v a , l ac k o f i n iti a ti v e w e r e m o r e c o mm on i n m e n S o ll a [ 26 ] C r o ss - s ec ti on a l s t udy ( I t a l y ) T o a ss e s s g e nd e r d i ff e r e n ce s i n m o t o r a nd non - m o t o r s y m p t o m s P D : 156 ( 58 . 3 ) H C : 132 ( 61 . 3 ) P D : 69 . 3 ( 8 . 5 ) H C : 69 . 8 ( 8 . 1 ) 6 . 3 ( 4 . 4 ) W o m e n p r e s e n t e d m o r e fr e qu e n tl y w it h t r e m o r a s i n iti a l s y m p t o m ( p \ 0 . 025 ) a nd w o r s e U P D R S i n s t a b ilit y s c o r e ( p \ 0 . 02 ) N on - M o t o r S y m p t o m s S ca l e ( N M SS ) s c o r e i n w o m e n w it h P D w a s s i gn i ﬁ ca n tl y h i gh e r t h a n t h a t i n m e n ( p \ 0 . 018 ) W o m e n w it h P D h a d h i gh e r s c o r e s i n ca r d i ov a s c u l a r ( p \ 0 . 002 ) , s l ee p / f a ti gu e ( p \ 0 . 018 ) a nd m ood / a p a t hy ( p \ 0 . 001 ) do m a i n s a nd h a d m o r e fr e qu e n tl y f a ti gu e ( p \ 0 . 03 ) , l ac k o f m o ti v a ti on ( p \ 0 . 015 ) a nd s a dn e ss ( p \ 0 . 009 ) M e n w it h P D r e po r t e d h i gh e r s c o r e s i n t h e s e xu a l dy s f un c ti on do m a i n ( p \ 0 . 017 ) a nd c o m p l a i n e d m o r e fr e qu e n tl y a lt e r e d i n t e r e s t i n s e x ( p \ 0 . 001 ) a nd c o m pu l s i v e s e xu a l b e h a v i o r ( p \ 0 . 001 ) S ong [ 30 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s on m o t o r a nd non - m o t o r s y m p t o m s i n d e novo p a ti e n t s 428 ( 60 . 3 ) 60 . 6 ( 10 . 7 ) 1 . 9 ( 1 . 7 ) W o m e n h a d m o r e d e p r e ss i v e s y m p t o m s M e n h a d h i gh e r s c o r e s f o r M i n i M e n t a l S t a t e E x a m i n a ti on ( MM S E ) N o s i gn i ﬁ ca n t d i ff e r e n ce s w e r e f ound f o r o t h e r N M S S ze w cz yk - K r o li ko w s k i [ 25 ] C r o ss - s ec ti on a l s t udy ( M u lti ce n t e r s t udy , UK ) T o d e li n ea t e e ff ec t s o f a g e a nd g e nd e r on P D ph e no t yp e i n a n i n c i d e n t c oho r t P D p a ti e n t s a nd H C fr o m t h e O x f o r d P a r k i n s on D i s ea s e C e n t r e ( O P D C ) P D : 490 ( 62 . 4 ) H C : 176 ( 36 . 4 ) P D : 67 . 9 ( 9 . 3 ) H C : 64 . 3 ( 9 . 1 ) 3 . 3 ( 2 . 4 ) M e n p r e s e n t e d i n c r ea s e d s e v e r it y a nd g r ea t e r s y m p t o m s y mm e t r y i n t h e f ace , n ec k a nd a r m s W o m e n h a d m o r e po s t u r a l p r ob l e m s M e n h a d m o r e s e v e r e c ogn iti v e i m p a i r m e n t , g r ea t e r r a t e o f RB D , m o r e o r t ho s t a ti c hypo t e n s i on a nd s e xu a l dy s f un c ti on 1590 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s U c [ 38 ] 5 - y ea r l ong it ud i n a l p r o s p ec ti v e s t udy ( I n t e r n a ti on a l M u lti ce n t e r s t udy - DA T A T O P c oho r t ) T o i nv e s ti g a t e t h e i n c i d e n ce a nd r i s k f ac t o r s o f c ogn iti v e i m p a i r m e n t 740 ( 66 . 5 ) 61 . 4 ( 9 . 6 ) 2 . 2 ( 1 . 3 ) 2 . 4 % h a d c ogn iti v e i m p a i r m e n t a t 2 y ea r s a nd 5 . 8 % a t 5 y ea r s C ogn iti v e i m p a i r m e n t w a s a ss o c i a t e d w it h o l d e r a g e , h a ll u c i n a ti on s , m a l e g e nd e r , i n c r ea s e d s y mm e t r y o f p a r k i n s on i s m , i n c r ea s e d s e v e r it y o f m o t o r i m p a i r m e n t ( e x ce p t f o r t r e m o r ) , s p eec h a nd s w a ll o w i ng i m p a i r m e n t s , d e x t e r it y l o ss , a nd p r e s e n ce o f g a s t r o e n t e r o l og i c a nd u r o l og i c i ss u e s a t b a s e li n e W ee [ 133 ] 18 - m on t h l ong it ud i n a l , p r o s p ec ti v e s t udy ( S i ng a po r e ) T o e x a m i n e t h e f ac t o r s t h a t p r e d i c t i nd i v i du a l t r a j ec t o r i e s o f a p a t hy 89 ( 73 ) 65 . 4 ( 7 . 8 ) 5 . 2 ( 3 . 8 ) A t b a s e li n e , a p a t hy w a s p r e s e n t i n 42 . 7 % M a l e g e nd e r , l o w e r e du ca ti on a l a tt a i n m e n t , h i gh e r d e p r e ss i on s y m p t o m s e v e r it y , m o r e s e v e r e f un c ti on a l d i s a b ilit y a nd t h e p r e s e n ce o f dy s k i n e s i a s a t b a s e li n e p r e d i c t e d i n c r ea s i ng a p a t hy ov e r t h e s ub s e qu e n t 18 m on t h s B i o m a r k e r s A s c h e r i o [ 48 ] 2 - y ea r l ong it ud i n a l p r o s p ec ti v e s t udy ( I n t e r n a ti on a l m u lti ce n t e r - DA T A T O P c oho r t ) T o d e t e r m i n e w h e t h e r s e r u m u r a t e p r e d i c t d i s ea s e p r og r e ss i on 774 ( 65 . 9 ) 62 m e d i a n \ 5 I n c r ea s i ng u r a t e p r e d i c t e d l o w e r U P D R S c h a ng e a nd l e ss n ee d f o r l e vodop a m o r e i n m e n t h a n i n w o m e n w it h P D B r i gh i n a , 2010 [ 43 ] C r o ss - s ec ti on a l ( I t a l y ) T o m ea s u r e a - s ynu c l e i n p r o t e i n i n l y m pho m ono c y t e s i n P D p a ti e n t s a nd H C P D : 78 ( 60 . 2 ) H C : 78 ( 57 . 7 ) P D : 65 . 1 ( 9 . 4 ) H C : 48 . 8 ( 18 . 2 ) 4 ( r a ng e 2 – 8 ) a l ph a - s ynu c l e i n l e v e l s w e r e no t s i gn i ﬁ ca n tl y d i ff e r e n t b e t w ee n P D a nd H C I n H C , a l ph a - s ynu c l e i n p r o t e i n l e v e l s i n c r ea s e d w it h a g e a nd w e r e h i gh e r i n m e n t h a n i n w o m e n C a r a n c i [ 45 ] C r o ss - s ec ti on a l ( I t a l y ) T o c o m p a r e t o t a l a - s ynu c l e i n p l a s m a c on ce n t r a ti on s i n P D p a ti e n t s a nd a g e - m a t c h e d H C P D : 69 ( 57 . 9 ) H C : 110 ( 51 . 8 ) P D : 65 . 2 ( 9 ) H C : 64 . 8 ( 8 ) 10 ( m e d i a n ) P l a s m a a l ph a - s ynu c l e i n w e r e d ec r ea s e d i n p a ti e n t s i n a dv a n ce d s t a g e i n m e n , bu t no t i n w o m e n P l a s m a a l ph a - s ynu c l e i n c on ce n t r a ti on w a s a ss o c i a t e d w it h c ogn iti v e i m p a i r m e n t s , h a ll u c i n a ti on s , a nd s l ee p d i s o r d e r s on l y i n m e n G a o [ 52 ] N e s t e d ca s e – c on t r o l s t udy ( M u lti ce n t e r , U S A ) T o e x a m i n e w h e t h e r h i gh e r p l a s m a u r a t e c on ce n t r a ti on s a r e a ss o c i a t e d w it h a l o w e r r i s k o f P D a nd w h e t h e r t h e r e i s a s e x d i ff e r e n ce i n t h e po t e n ti a l u r a t e – P D r e l a ti o n s h i p P D : 388 ( 52 ) H C : 1 . 267 ( 35 ) P D : NA H C : 60 . 7 NA H i gh e r b a s e li n e u r a t e w a s a ss o c i a t e d w it h l o w e r P D r i s k i n m e n ( RR : 0 . 59 , 95 % C I 0 . 35 – 0 . 99 , p = 0 . 018 ) , bu t no t i n w o m e n ( RR : 1 . 06 , 95 % C I 0 . 66 – 1 . 71 , p = 0 . 38 ) A m e t a - a n a l y s i s i n c l ud i ng f u r t h e r 325 P D ca s e s fr o m 3 ongo i ng U S p r o s p ec ti v e s t ud i e s c on ﬁ r m e d t h e r e l a ti on s h i p b e t w ee n P D r i s k a nd u r a t e i n m e n ( RR : 0 . 63 , 95 % C I 0 . 42 t o 0 . 95 , p = 0 . 03 ) , bu t no t i n w o m e n ( RR : 0 . 89 , 95 % C I 0 . 57 – 1 . 40 , p = 0 . 52 ) H o [ 46 ] C r o ss - s ec ti on a l s t udy ( K o r ea ) T o c o m p a r e l e v e l s o f L RR K 2 , a - s ynu c l e i n , a nd D J - 1 i n u r i n e e xo s o m e s fr o m P D p a ti e n t s a nd H C P D : 26 ( 53 . 8 ) H C : 21 ( 47 . 6 ) P D : 73 ( 2 . 1 ) H C : 70 ( 3 . 2 ) 5 . 8 ( 0 . 6 ) N o d i ff e r e n ce i n L RR K 2 , a l ph a - s ynu c l e i n , a nd D J - 1 u r i n e e xo s o m e s i n P D c o m p a r e d t o H C D J - 1 u r i n e e xo s o m e l e v e l w a s s i gn i ﬁ ca n tl y h i gh e r ( 1 . 7 - f o l d ) a nd a g e - r e l a t e d i n m e n w it h P D t h a n i n H C I k e d a [ 44 ] C r o ss - s ec ti on a l s t udy ( J a p a n ) T o c o m p a r e s e r u m u r a t e , p a r a oxon a s e - 1 , i r on , f e rr iti n a nd li p i d i n P D p a ti e n t s a nd H C P D : 119 ( 47 ) H C : 120 ( 50 ) P D : 73 . 4 ( 8 . 7 ) H C : 72 . 9 ( 8 . 8 ) 6 . 9 ( 5 . 1 ) S e r u m l e v e l s o f t o t a l c ho l e s t e r o l a nd l o w d e n s it y li pop r o t e i n - c ho l e s t e r o l w e r e i nv e r s e l y r e l a t e d t o P D s t a g e a nd du r a ti on i n w o m e n J Neurol ( 2017 ) 264 : 1583 – 1607 1591 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s J a i n [ 134 ] C o mm un it y - b a s e d c oho r t ( M u lti ce n t e r , U S A ) T o i nv e s ti g a t e t h e r e l a ti on s h i p b e t w ee n s e r u m u r a t e a nd P D r i s k P D : 154 H C : 5 . 749 ( 39 . 5 ) P D : 72 . 8 H C : 73 ( 5 . 6 ) NA U r a t e c on ce n t r a ti on s w e r e l o w e r i n w o m e n t h a n m e n [ 316 . 8 ( 88 ) l m o l / l v e r s u s 367 . 4 ( 87 . 7 ) l m o l / l , p \ 0 . 0001 ] a nd i n w o m e n no a ss o c i a ti on b e t w ee n u r a t e a nd P D r i s k w a s ob s e r v e d I n m e n , t h e P D r i s k w a s s i gn i ﬁ ca n tl y i n c r ea s e d f o r u r a t e \ 300 l m o l / l ( O R : 1 . 69 , 95 % C I 1 . 03 – 2 . 78 ) J e s u s [ 50 ] C r o ss - s ec ti on a l s t udy ( S p a i n ) T o i nv e s ti g a t e w h e t h e r u r a t e i s r e l a t e d t o c li n i ca l p a r a m e t e r s o f t h e d i s ea s e P D : 161 ( 55 . 9 ) H C : 178 ( 60 . 6 ) P D : 63 . 2 ( 11 . 9 ) H C : 60 . 5 ( 13 . 6 ) 9 ( 6 . 6 ) S e v e r it y o f P D w a s r e l a t e d t o u r a t e w h e n c on s i d e r i ng bo t h s e x e s o r m e n on l y bu t no t i n w o m e n on l y LE DD w a s i nv e r s e l y a ss o c i a t e d w it h u r a t e l e v e l s i n m e n on l y M c F a r l a nd [ 51 ] P o s t m o r t e m s t udy ( U S A ) T o e xp l o r e w ea t h e r l o w e r u r a t e i n b r a i n i s a ss o c i a t e d w it h P D P D : 17 ( 47 ) H C : 13 ( 61 . 5 ) P D : 79 . 2 ( 7 . 5 ) H C : 78 . 3 ( 11 . 3 ) NA U r a t e l e v e l s i n c o r ti ca l a nd s t r i a t a l ti ss u e t r e nd e d l o w e r i n P D c o m p a r e d t o c on t r o l s i n m a l e s on l y S c h w a r t z s c h i e l d [ 47 ] L ong it ud i n a l s t udy ( M u lti ce n t e r — P E RC E P T c oho r t ) T o d e t e r m i n e w h e t h e r s e r u m u r a t e p r e d i c t s p r ogno s i s 804 ( 64 . 3 ) 59 ( m e d i a n ) \ 5 I n c r ea s e d b a s e li n e u r a t e r e du ce t h e n ee d f o r dop a m i n e r g i c t r ea t m e n t T h i s a ss o c i a ti on w a s m a r k e d l y s t r ong e r i n m e n ( H R = 0 . 39 ; 95 % C I 0 . 26 – 0 . 60 ; p \ 0 . 0001 ) t h a n i n w o m e n ( H R = 0 . 77 ; 95 % C I 0 . 39 t o 1 . 50 ; p = 0 . 4 ) T h e p e r ce n t l o ss i n s t r i a t a l [ 123 I ] b - C I T up t a k e a l s o i m p r ov e d w it h i n c r ea s i ng s e r u m u r a t e c on ce n t r a ti on s ( ov e r a ll p f o r t r e nd = 0 . 002 ; m e n , p = 0 . 0008 ; w o m e n , p = 0 . 4 ) S c h w a r t z s c h i e l d [ 49 ] C r o ss - s ec ti on a l s t udy ( M u lti ce n t e r - P E RC E P T c oho r t ) T o i nv e s ti g a t e w h e t h e r h i gh e r l e v e l s o f u r a t e i s a p r e d i c t o r o f h a v i ng a dop a m i n e t r a n s po r t e r b r a i n s ca n w it ho u t e v i d e n ce o f dop a m i n e r g i c d e ﬁ c it 797 ( 63 . 9 ) 59 . 4 ( 11 . 6 ) \ 5 O dd s o f h a v i ng a s ca n w it hou t e v i d e n ce o f dop a m i n e r g i c d e ﬁ c it r o s e ac r o ss i n c r ea s i ng qu i n til e s o f u r a t e l e v e l , w it h a n a g e a nd g e nd e r - a d j u s t e d odd s r a ti o o f 3 . 2 c o m p a r i ng t h e h i gh e s t t o t h e l o w e s t u r a t e qu i n til e ( 95 % C I 1 . 5 t o 7 . 2 ; p f o r t r e nd = 0 . 0003 ) T h e a ss o c i a ti on w a s s i gn i ﬁ ca n t i n m e n bu t no t i n w o m e n , r e g a r d l e ss o f w h e t h e r c o mm on o r s e x - s p ec i ﬁ c qu i n til e s o f u r a t e w e r e u s e d G e n e ti c s A g a lli u [ 67 ] C r o ss - s ec ti on a l ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o e x a m i n e t h e a ss o c i a ti on b e t w ee n L RR K 2 G 2019 S m u t a ti on a nd ca n ce r a m ong P D p a ti e n t s 1 . 549 ( 56 . 1 ) 70 . 9 ( 10 . 8 ) 9 . 8 ( 7 ) 177 ( 11 . 4 % ) L RR K 2 G 2019 S m u t a ti on ca rr i e r s w e r e i d e n ti ﬁ e d M u t a ti on ca rr i e r s w e r e young e r a t P D d i a gno s i s a nd m o r e li k e l y t o b e w o m e n ( 53 . 1 % ) a nd o f A s hk e n az i J e w i s h d e s ce n t ( 76 . 8 % ) i n c o m p a r i s on w it h non - ca rr i e r s C ili a , 2014 [ 68 ] C r o ss - s ec ti on a l s t udy ( I t a l y ) T o i nv e s ti g a t e w h e t h e r o r no t L RR K 2 s t a t u s i n ﬂ u e n ce s g e nd e r d i s t r i bu ti on a nd P D ph e no t yp e 2 . 392 ( 59 . 2 ) 65 . 6 ( 9 . 9 ) 11 . 9 ( 6 . 5 ) L RR K 2 m u t a ti on s w e r e i d e n ti ﬁ e d i n 40 P D p a ti e n t s ( 1 . 6 % ) N o m a j o r c li n i ca l d i ff e r e n ce s w e r e f ound b e t w ee n L RR K 2 - ca rr i e r s a nd non - ca rr i e r s F e m a l e g e nd e r w a s m o r e c o mm on a m ong s t ca rr i e r s t h a n non - ca rr i e r s ( 57 % v s . 40 % ; p = 0 . 01 ) , w it hou t a ny g e nd e r - r e l a t e d d i ff e r e n ce i n c li n i ca l f ea t u r e s 1592 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s C l a r k [ 69 ] C r o ss - s ec ti on a l s t udy ( U S A ) T o e v a l u a t e t h e fr e qu e n c y o f L RR K 2 m u t a ti on s i n P D P D : 504 ( 60 . 3 ) H C : 314 P D : 60 . 8 ( 11 . 5 ) 7 . 8 ( 6 ) L RR K 2 G 2019 S m u t a ti on w a s p r e s e n t i n 28 ca s e s w it h P D ( 5 . 6 % ) a nd 2 H C ( 0 . 6 % ) ( O R : 9 . 18 , 95 % C I 2 . 17 t o 38 . 8 , p \ 0 . 01 ) M u t a ti on ca rr i e r s w e r e m o r e fr e qu e n tl y w o m e n c o m p a r e d t o non - ca rr i e r s ( 60 . 7 % v e r s u s 38 . 4 % , p = 0 . 03 ) F o lt yn i e [ 53 ] C r o ss - s ec ti on a l s t udy ( UK ) T o i nv e s ti g a t e t h e i m p ac t o f B DN F V a l / M e t po l y m o r ph i s m s on fr on t a l t a s k s i n P D p a ti e n t s 291 ( 60 . 4 ) 59 . 4 NA P a ti e n t s w it h l o w r a t e s o f B DN F s ec r e ti on ( M e t a ll e l e s ) p e rf o r m e d s i gn i ﬁ ca n tl y b e tt e r i n fr on t a l t a s k s t h a n t ho s e w it h h i gh r a t e s o f s ec r e ti on ( V a l a ll e l e s ) S ubg r oup a n a l y s e s r e v ea l e d t h a t t h e e ff ec t i s m o s t a pp a r e n t i n w o m e n a nd a m ong p a ti e n t s w it h p r i o r dop a m i n e r g i c e xpo s u r e G a n - O r [ 74 ] M e t a - a n a l y s i s i n c l ud i ng 17 ca s e – c on t r o l s t ud i e s T o c ond u c t a s e x - s t r a ti ﬁ e d m e t a - a n a l y s i s , e x a m i n i ng w h e t h e r t h e g e n e ti c d a t a s uppo r t t h e hypo t h e s i s o f a s e x e ff ec t i n L RR K 2 - a ss o c i a t e d P D 24 . 088 ( 58 . 7 ) NA NA A t o t a l o f 1080 L RR K 2 - a ss o c i a t e d P D p a ti e n t s w e r e i d e n ti ﬁ e d A m ong m e n , L RR K 2 m u t a ti on ca rr i e r s h a d a poo l e d O R f o r P D o f 4 . 20 ( 95 % C I 2 . 95 – 5 . 99 , p \ 0 . 0001 ) a nd a m ong w o m e n , L RR K 2 m u t a ti on ca rr i e r s h a d a poo l e d O R f o r P D o f 4 . 73 ( 95 % C I 3 . 26 – 6 . 86 , p \ 0 . 0001 ) T h e M : F r a ti o w a s 1 . 02 : 1 . 00 ( 50 . 6 % m e n a nd 49 . 4 % w o m e n ) G a tt [ 54 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o v e r i f y i f m it o c hond r i a l t r a n s c r i p t o r f ac t o r A S N P r s 230 6 604 g e no t yp e fr e qu e n c i e s a r e a ss o c i a t e d w it h P DD P DD : 63 H C : 56 NA NA M it o c hond r i a l t r a n s c r i p t o r f ac t o r A S N P r s 2306604 g e no t yp e fr e qu e n c i e s i n t h e P DD m a l e g r oup w e r e s i gn i ﬁ ca n tl y d i ff e r e n t fr o m t h e m a l e c on t r o l s ( p = 0 . 002 ) H o m o z ygo s it y f o r t h e A a ll e l e w a s s t r ong l y a ss o c i a t e d w it h a n i n c r ea s e d r i s k o f P D i n m a l e s ( O R = 5 . 570 , p = 0 . 001 , ) c o m p a r e d w it h AG / GG ca rr i e r s G u s don [ 55 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o d e t e r m i n e w h e t h e r m t - ND 2 5178 A / C po l y m o r ph i s m i s a ss o c i a t e d w it h a r e du ce d P D r i s k P D : 484 ( 54 . 6 ) H C : 710 ( 46 . 7 ) P D : 60 . 6 ( 10 . 1 ) H C : 68 . 4 ( 10 . 6 ) NA T h e r e w a s no s i gn i ﬁ ca n t a ss o c i a ti on b e t w ee n m t - ND 2 5178 A / C po l y m o r ph i s m a nd P D w h e n a n a l y z i ng t h e e n ti r e popu l a ti on S ubg r oup a n a l y s i s r e v ea l e d t h a t i n m a l e s t h e fr e qu e n c y o f 5178 A w a s s i gn i ﬁ ca n tl y l o w e r i n P D p a ti e n t s ( 20 . 0 % v e r s u s 27 . 7 % , p = 0 . 027 ) K l e b e [ 56 ] C r o ss - s ec ti on a l s t udy ( I n t e r n a ti on a l m u lti ce n t e r s t udy ) T o t e s t w h e t h e r t h e V a l 158 M e t po l y m o r p h i s m i s a m od i ﬁ e r o f t h e a g e a t on s e t i n P D P D : 5 . 886 ( s e x r a ti o : 1 . 5 ) H C : 10 . 723 ( s e x r a ti o : 1 . 01 ) P D : 57 . 6 ( 13 . 8 ) H C : 60 ( 10 . 1 ) NA T h e d i s t r i bu ti on o f t h e C O M T po l y m o r ph i s m w a s no t d i ff e r e n t i n p a ti e n t s a nd c on t r o l s ( p = 0 . 22 ) P a ti e n t s w it h t h e V a l / V a l h a d young e r a g e a t on s e t ( 57 . 1 ± 13 . 9 , p = 0 . 03 ) t h a n t h e V a l / M e t ( 57 . 4 ± 13 . 9 ) a nd t h e M e t / M e t g e no t yp e s ( 58 . 3 ± 13 . 5 ) T h e d i ff e r e n ce w a s g r ea t e r i n m e n ( 1 . 9 y ea r s b e t w ee n V a l / V a l a nd M e t / M e t , p = 0 . 007 ) t h a n i n w o m e n ( 0 . 2 y ea r s , p = 0 . 81 ) J Neurol ( 2017 ) 264 : 1583 – 1607 1593 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s L i n [ 57 ] C r o ss - s ec ti on a l s t udy ( T a i w a n ) T o i nv e s ti g a t e t h e a ss o c i a ti on o f a 1 - a n ti c hy m o t r yp s i n g e n e p o l y m o r ph i s m a nd P D P D : 210 ( s e x r a ti o 1 . 14 ) H C : 260 ( s e x r a ti o 1 . 15 ) P D : 63 . 6 ( 11 . 5 ) H C : 63 . 7 ( 11 . 1 ) 5 . 2 ( 4 . 9 ) N o d i ff e r e n ce s o f a ll e li c fr e qu e n c y ( A a nd T ) a nd g e no t yp e po l y m o r ph i s m ( AA , A T a nd TT ) o f t h e a 1 - a n ti c hy m o t r yp s i n g e n e i n P D p a ti e n t s a nd H C T h e r e w e r e s i gn i ﬁ ca n tl y f e w e r ea r l y - on s e t P D ( on s e t a g e young e r t h a n 60 y ea r s ) o r P D w o m e n ca rr y i ng t h e ho m o z ygo t e AA g e no t yp e ( a 1 - a n ti c hy m o t r yp s i n - AA ) t h a n H C ( p = 0 . 046 a nd 0 . 044 , r e s p ec ti v e l y ) R e du ce d r i s k o f a 1 - a n ti c hy m o t r yp s i n - AA w a s p a r ti c u l a r l y s i gn i ﬁ ca n t a m ong P D w o m e n w it h a g e a t on s e t young e r t h a n 60 y ea r s ( O R : 0 . 796 , 95 % C I 0 . 749 – 0 . 847 , p \ 0 . 0001 ) L i n [ 58 ] C r o ss - s ec ti on a l s t udy ( T a i w a n ) T o e v a l u a t e a po ss i b l e r e l a ti on s h i p b e t w ee n t h e p C D 14 po l y m o r ph i s m a nd t h e r i s k o f P D P D : 200 ( 56 ) H C : 200 ( 56 ) P D : 64 . 5 ( 11 . 3 ) H C : 64 . 5 ( 6 . 6 ) 5 ( 4 . 7 ) R e s u lt s r e v ea l e d t h a t t h e C D 14 - T a ll e l e o f t h e p C D 14 po l y m o r ph i s m w a s d i ff e r e n t i n f e m a l e P D p a ti e n t s c o m p a r e d t o f e m a l e c on t r o l s ( O R = 1 . 262 , p = 0 . 038 ) , bu t no d i ff e r e n ce w a s f ound i n m a l e s . F e m a l e i nd i v i du a l s w it h ho m o z ygo t e C D 14 - TT g e no t yp e h a d i n c r ea s e d P D r i s k o f 1 . 28 ti m e ( p = 0 . 027 ) L i u [ 59 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o i nv e s ti g a t e t h e a ss o c i a ti on b e t w ee n CC D C 62 r s 128 1 7488 a nd P D P D : 341 ( 52 . 2 ) H C : 423 ( 53 . 4 ) NA NA CC D C 62 r s 12817488 A a ll e l e i s a ss o c i a t e d w it h P D d i a gno s i s ( p = 0 . 006 ) i n C h i n e s e popu l a ti on T h e a ss o c i a ti on o f r s 12817488 w it h P D w a s on l y f ound i n f e m a l e s M a r i a n i [ 60 ] C r o ss - s ec ti on a l s t udy ( I t a l y ) T o v e r i f y t h e r o l e o f i r on s t a t u s i n P D P D : 92 ( 67 . 4 ) H C : 358 ( 35 . 8 ) P D : 70 m e d i a n ( r a ng e 30 - 8 3 ) H C : 62 m e d i a n ( r a ng e 31 – 8 7 ) 7 ( 4 . 5 ) N o s i gn i ﬁ ca n t d i ff e r e n ce s i n t h e D 544 E a nd R 793 H v a r i a n t s o f t h e ce r u l op l a s m i n g e n e , t h e P 589 S v a r i a n t o f t h e t r a n s f e rr i n g e n e , a nd t h e H 63 D a nd C 282 Y v a r i a n t s o f t h e hu m a n h e m o c h r o m a t o s i s p r o t e i n g e n e b e t w ee n p a ti e n t s a nd H C W h e n t h e e ff ec t o f s e x w a s c on s i d e r e d i n t h e s t a ti s ti ca l m od e l , a n i n c r ea s e o f t h e p r ob a b ilit y o f h a v i ng P D i s a ss o c i a t e d w it h l o w i r on c on ce n t r a ti on a nd t r a n s f e rr i n - s a t u r a ti on O rr - U r t r e g e r [ 70 ] C r o ss - s ec ti on a l s t udy ( I s r ae l ) T o a ss e ss t h e o cc u rr e n ce o f t h e L RR K 2 m u t a ti on s i n J e w i s h I s r ae li P D p a ti e n t s P D : 427 ( 64 . 2 ) H C : 1 . 802 ( NA ) P D : 67 . 6 ( 10 . 2 ) H C : r a ng e 20 – 45 NA W o m e n w e r e s i gn i ﬁ ca n tl y ov e r - r e p r e s e n t e d a m ong t h e G 2019 S m u t a ti on ca rr i e r s P a l ac i o s [ 61 ] N e s t e d ca s e – c on t r o l s t udy ( M u lti ce n t r i c , U S A ) T o e x a m i n e a ss o c i a ti on s b e t w ee n po l y m o r ph i s m s o f ca ff e i n e m e t a bo li z i ng g e n e s ( C Y P 1 A 2 a nd NA T 2 ) a nd P D r i s k P D : 298 ( 46 . 6 ) H C : 1285 ( 43 . 6 ) NA NA T h e C Y P 1 A 2 r s 762551 ( p a r t o f t h e c y t o c h r o m e P 450 s y s t e m ) po l y m o r ph i s m ( l o w e r e n z y m e i ndu c i b ilit y ) w a s m a r g i n a ll y a ss o c i a t e d w it h a n i n c r ea s e d r i s k o f P D ( RR = 1 . 34 ; 95 % C I 1 . 02 , 1 . 78 ) i n w o m e n , bu t no t i n m e n 1594 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s S a n L u c i a no [ 62 ] C r o ss - s ec ti on a l s t udy ( U S A ) T o t e s t w ea t h e r t h e 174 G [ C ( r s 1800795 ) s i ng l e nu c l e o ti d e po l y m o r ph i s m ( S N P ) i n t h e p r o m o t e r o f t h e i n t e r l e uk i n - 6 ( I L 6 ) g e n e a nd t h e 1730 G [ A ( r s 4986938 ) S N P i n t h e e s t r og e n r ece p t o r b e t a ( E S R 2 ) m a y i n ﬂ u e n ce t h e P D r i s k P D : 380 ( bo t h A s hk e n az i J e w i s h a nd non - J e w s ) H C : 522 NA NA T h e G a ll e l e o f t h e - 174 G [ C S N P w a s m o r e c o mm on i n J e w i s h P D ca s e s ( p = 0 . 033 ) a s w e ll a s i n non - J e w i s h m e n w it h P D ( p = 0 . 022 ) T h e GG g e no t yp e i n c r ea s e d t h e r i s k o f P D by ov e r t w o f o l d i n non - J e w i s h m e n ( O R = 2 . 11 , 95 % C I 1 . 14 – 3 . 89 , p = 0 . 017 ) , a nd a pp r o ac h e d s i gn i ﬁ ca n ce i n t h e t o t a l J e w i s h g r oup w it h P D ( O R = 1 . 42 , 95 % C I 0 . 97 – 2 . 06 , p = 0 . 067 ) T h e A a ll e l e o f t h e E S R 2 1730 G [ A S N P w a s a ss o c i a t e d w it h a d ec r ea s e d r i s k f o r P D i n J e w i s h w o m e n S a und e r s - P u ll m a n [ 71 ] C r o ss - s ec ti on a l s t udy ( U S A ) T o t e s t w h e t h e r t h e r e i s a n i n c r ea s e d g e n e ti c c o m pon e n t i n w o m e n o f J e w i s h b ac kg r ound a nd a ss e ss w h e t h e r p a r k i n s on i s m i s m o r e fr e qu e n t i n f a m il y m e m b e r s o f w o m e n w it h P D i n c o m p a r i s on w it h f a m il y m e m b e r s o f m e n w it h P D , a d j u s ti ng f o r L RR K 2 G 2019 S m u t a ti on s i n t h e p r ob a nd P D : 177 ( 52 . 5 ) 66 . 6 ( 11 . 6 ) NA U s i ng C ox p r opo r ti on a l h aza r d s m od e l s t o e v a l u a t e t h e r i s k o f p a r k i n s on i s m a m ong f a m il y m e m b e r s o f P D s ub j ec t s , h a v i ng a d a ugh t e r w it h P D c o m p a r e d w it h a s on w a s a ss o c i a t e d w it h i n c r ea s e d r i s k o f p a r k i n s on i s m i n t h e p a r e n t ( H R 2 . 59 , p = 0 . 014 ) a s w a s h a v i ng a c h il d w it h a L RR K 2 G 2019 S m u t a ti on ( H R 3 . 19 , p = 0 . 003 ) T h e i n c r ea s e d r i s k a m ong p a r e n t s o f w o m e n w it h P D p e r s i s t e d w h e n a d j u s ti ng f o r L RR K 2 s t a t u s ( H R 2 . 19 , p = 0 . 023 ) S i m i nuv i c [ 63 ] P D : 10 ( 70 ) H C : 9 ( 66 . 6 ) T o d e t e r m i n e g e nd e r d i ff e r e n ce s i n t h e g e n e e xp r e ss i on p r o ﬁ l e s o f dop a m i n e n e u r on s NA NA NA D i ff e r e n t p a tt e r n s o f d e r e gu l a ti on b e t w ee n m a l e s a nd f e m a l e s w it h m o r e p r o m i n e n t do w n r e gu l a ti on o f g e n e s r e l a t e d t o ox i d a ti v e pho s pho r y l a ti on , a pop t o s i s , s yn a p ti c t r a n s m i ss i on a nd t r a n s m i ss i on o f n e r v e i m pu l s e i n t h e m a l e P D popu l a ti on Y u [ 64 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o e v a l u a t e t h e po ss i b l e a ss o c i a ti on b e t w ee n r s 128 1 7488 po l y m o r ph i s m i n t h e CC D C 62 / H I P 1 R g e n e a nd P D P D : 515 H C : 518 NA NA T h e r s 12817488 po l y m o r ph i s m i n t h e CC D C 62 / H I P 1 R g e n e i s a ss o c i a t e d w it h P D ( p = 0 . 003 ) a nd t h a t t h e g e no t yp e a nd a ll e l e fr e qu e n c i e s a r e p r e v a l e n t l a t e - on s e t P D p a ti e n t s a nd m a l e c on t r o l s ( p = 0 . 025 a nd p = 0 . 007 , r e s p ec ti v e l y ) Z h a ng [ 65 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o i nv e s ti g a t e t h e r e l a ti on s h i p b e t w ee n N C A P D 2 po l y m o r ph i s m s a nd t h e r i s k o f P D P D : 265 ( 58 . 9 ) H C : 269 ( 59 . 9 ) NA NA T h e A a ll e l e o f r s 7311174 a nd t h e T a ll e l e o f r s 2072374 o f t h e N C A P D 2 g e n e r e du ce d P D r i s k i n m a l e p a ti e n t s ( p = 0 . 016 a nd p = 0 . 019 , r e s p ec ti v e l y ) Z h a o , 2015 [ 66 ] C r o ss - s ec ti on a l s t udy ( C h i n a ) T o e v a l u a t e w h e t h e r g e n e ti c po l y m o r ph i s m s o f t h e TL R 4 g e n e a r e a ss o c i a t e d w it h P D s u s ce p ti b ilit y P D : 380 ( 62 ) H C : 380 ( 60 . 2 ) P D : 62 . 5 ( 10 . 8 ) H C : 70 . 4 ( 8 . 2 ) 4 . 4 ( 3 . 6 ) T h e fr e qu e n c y o f r s 1927914 C a ll e l e o f t h e TL R 4 g e n e w a s s i gn i ﬁ ca n tl y r e du ce d i n m a l e P D c o m p a r e d t o m a l e H C ( O R = 0 . 714 , 95 % C I 0 . 549 – 0 . 929 , p = 0 . 012 ) D i ff e r e n ce s i n m a n a g e m e n t : ph a r m ac o l og i ca l t r ea t m e n t A r a b i a [ 85 ] C on s ec u ti v e , c li n i c - b a s e d c oho r t s t udy ( I t a l y ) T o e x a m i n e t h e r e l a ti on s h i p b e t w ee n body w e i gh t a nd l e vodop a ph a r m ac ok i n e ti c 164 ( 55 . 5 ) ( 65 P D p a ti e n t s w it h L I D ) 65 . 5 ( 8 . 9 ) 83 . 7 ( 59 . 8 ) B ody w e i gh t w a s i nv e r s e l y c o rr e l a t e d w it h l e vodop a a r ea und e r t h e c u r v e ( AU C ) a nd h a l f - li f e ( T 1 / 2 ) ( p \ 0 . 001 a nd p \ 0 . 001 ) W o m e n w e r e li gh t e r t h a n m e n ( 65 . 3 v e r s u s 73 . 9 kg , p \ 0 . 001 ) , m o r e dy s k i n e ti c ( 53 . 4 v e r s u s 28 . 6 % , p 0 . 001 ) a nd h a d g r ea t e r AU C v a l u e s ( 6 . 45 v e r s u s 4 . 94 l m o l / l h , p = 0 . 002 ) J Neurol ( 2017 ) 264 : 1583 – 1607 1595 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s B a b a [ 78 ] L a r g e , c on s ec u ti v e , c li n i c - b a s e d c oho r t s t udy ( U S A ) T o d e t e r m i n e g e nd e r d i ff e r e n ce s i n t h e P D ph e no t yp e 1 . 264 ( 67 ) A g e a t on s e t : m e n 63 ( 11 . 1 ) , w o m e n 63 . 8 ( 11 ) M e n 7 . 2 ( 6 . 4 ) W o m e n 6 . 8 ( 6 . 4 ) T h e p r opo r ti on o f i nd i v i du a l s t a k i ng a n ti p a r k i n s on i a n m e d i ca ti on s d i d no t d i ff e r b e t w ee n g e nd e r ( 65 % a nd 67 % f o r m e n a nd w o m e n , r e s p ec ti v e l y ) LE DD w a s h i gh e r f o r m e n t h a n w o m e n ( 618 . 9 ± 409 . 1 v e r s u s 526 . 8 ± 365 . 1 m g , p \ 0 . 01 ) W o m e n h a d m o r e s e v e r e dy s k i n e s i a s c o r e t h a n m e n ( 1 . 1 ± 2 . 4 v e r s u s 0 . 8 ± 2 . 1 ; p \ 0 . 05 ) K o m po liti [ 82 ] P l ace bo - c on t r o ll e d , doub l e - b li nd , p a r a ll e l - d e s i gn s t udy T o c o m p a r e t h e ph a r m ac ok i n e ti c s o f l e vodop a a nd p r a m i p e xo l e ( PP X ) i n m e n a nd w o m e n ; t o i nv e s ti g a t e g e nd e r e ff ec t o f a d j un c t PP X t r ea t m e n t on l e vodop a ph a r m a c ok i n e ti c s 26 ( 46 . 1 ) M e n : 68 . 9 ( 5 . 1 ) W o m e n : 69 . 3 ( 6 . 9 ) NA A t b a s e li n e a f t e r l e vodop a a d m i n i s t r a ti on ( 100 m g ) , w o m e n h a d a h i gh e r m ea n l e vodop a AU C w ( 42 . 3 ± 7 m g v e r s u s 23 . 3 ± 7 . 3 ; p = 0 . 0001 ) a nd h i gh e r m ea n C m a x ( 1388 ± 42 m g v e r s u s 800 ± 33 m g ; p = 0 . 0019 ) T h e s e s e x d i ff e r e n ce s f o r l e vodop a ph a r m ac ok i n e ti c s w a s s u s t a i n e d ov e r l o w a nd h i gh do s e s o f PP X N o d i ff e r e n ce s i n PP X ph a r m ac ok i n e ti c s b e t w ee n m e n a nd w o m e n K u m a g a i [ 86 ] C li n i c - b a s e d c oho r t s t udy ( J a p a n ) T o a n a l y ze s e x d i ff e r e n ce s i n t h e l e vodop a ph a r m a c ok i n e ti c s i n P D 128 ( 40 . 1 ) 77 . 9 ( 6 . 3 ) 3 . 2 ( 2 . 4 ) T h e l e vodop a AU C a nd t h e AU C a d j u s t e d f o r body w e i gh t w e r e f ound t o b e s i gn i ﬁ ca n tl y g r ea t e r i n w o m e n c o m p a r e d w it h m e n ( p \ 0 . 0001 a nd p \ 0 . 0001 , r e s p ec ti v e l y ) I n t h e e l d e r l y p a ti e n t s ( [ 75 y ea r s o l d ) , t h e AU C a nd t h e AU C a d j u s t e d f o r body w e i gh t w e r e s i gn i ﬁ ca n tl y g r ea t e r i n w o m e n ( p \ 0 . 0001 a nd p \ 0 . 0001 , r e s p ec ti v e l y ) L ubo m s k i [ 80 ] C r o ss - s ec ti on a l s t udy ( 3 ce n t r e s i n A u s t r a li a ) T o e v a l u a t e s e x - r e l a t e d d i ff e r e n ce s a t on s e t i n p a ti e n t s w it h P D 210 ( 61 . 4 ) 69 . 1 ( 10 . 8 ) 7 . 3 ( 5 . 7 ) W o m e n r e po r t e d a s i gn i ﬁ ca n tl y l o w e r m ea n d a il y LE DD t h a n m e n ( 750 . 7 ± 472 . 2 m g v e r s u s 898 . 1 ± 481 . 3 m g , p = 0 . 03 ) L e vodop a r e qu i r e m e n t i n m a n w a s s i gn i ﬁ ca n tl y h i gh e r t h a n i n w o m e n a nd t h i s t r e nd p e r s i s t e d e v e n a f t e r c on t r o lli ng f o r a g e , d i s ea s e du r a ti on a nd s e v e r it y ( p \ 0 . 05 ) L yon s [ 135 ] R e t r o s p ec ti v e s t udy ( U S A ) T o e v a l u a t e s e x - r e l a t e d d i ff e r e n ce s i n P D p a ti e n t s 630 ( 50 ) 71 . 1 ( 7 . 6 ) 4 . 6 ( 4 . 6 ) W o m e n h a d h i gh e r MM S E a nd g r ea t e r dy s k i n e s i a p r e v a l e n ce M e n h a d h i gh e r U P D R S a nd w e r e t r ea t e d w it h g r ea t e r LE DD N yho l m [ 81 ] N a ti on w i d e ph a r m ac o - e p i d e m i o l og i ca l s u r v e y ( u s i ng d a t a fr o m ‘‘ p r e s c r i b e d d r ug r e g i s t e r’’ , S w e d e n ) T o i nv e s ti g a t e d i ff e r e n ce s i n t h e u s e a nd r e qu i r e m e n t o f l e vodop a i n P D T o s t ud y t h e c h a r ac t e r i s ti c s o f l o w - do s e a nd h i gh - do s e p a ti e n t s w it h P D 33 . 534 ( 46 . 5 ) ( w it h a t l ea s t on e pu r c h a s e o f l e vodop a ) H i gh do s e g r oup ( C 1200 m g ) : 67 . 7 ( NA ) L o w - do s e g r oup ( B 400 m g ) : 70 . 5 ( NA ) NA T h e m e d i a n d a il y do s e w a s 465 m g f o r m e n a nd 395 m g f o r w o m e n ( p \ 0 . 0001 ) S i gn i ﬁ ca n tl y , m o r e m e n w e r e t r ea t e d w it h do s e s [ 1200 m g d a il y T h e r e w a s a p r e do m i n a n ce o f m e n i n t h e h i gh l e vodop a do s e g r oup s , a d m i n i s t e r e d bo t h p e r o s ( 69 % v e r s u s 57 % ; p : n s ) a nd i n f u s i on ( 77 v e r s u s 56 % ; p : n s ) 1596 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s M a r ti n e lli [ 87 ] C li n i c - b a s e d c oho r t s t udy ( I t a l y ) T o e x a m i n e t h e po t e n ti a l s e x - r e l a t e d d i ff e r e n ce s i n l e vodop a ph a r m ac ok i n e ti c s a nd t h e i r r e l a ti on w it h t h e p r e s e n c e o f dy s k i n e s i a s 115 ( 58 . 3 ) M e n : 61 ( 11 ) W o m e n : 59 ( 9 ) M e n : 6 . 2 ( 4 . 9 ) W o m e n : 6 . 4 ( 4 . 0 ) T h e a r ea und e r t h e l e vodop a p l a s m a c on ce n t r a ti on ti m e c u r v e , c o rr ec t e d f o r t h e L D t e s t do s e ( AU C w ) w a s h i gh e r i n w o m a n t h a n i n m e n ( p \ 0 . 003 ) a nd c l ea r a n ce v a l u e s w a s r e du ce d i n w o m e n ( p \ 0 . 003 ) D y s k i n e s i a s w e r e p r e s e n t i n 38 p a ti e n t s ( 33 % ) bu t no s e x - r e l a t e d d i ff e r e n ce s w e r e ob s e r v e d M a r ti n ez - R a m i r ez [ 88 ] R e t r o s p ec ti v e s t udy ( U S A ) T o f o r m u l a t e a d e ﬁ n iti on a nd d e s c r i b e t h e c li n i ca l c h a r ac t e r i s ti c s o f P D p a ti e n t s w it h a ‘‘ b r ittl e r e s pon s e ’’ ( BR ) t o m e d i ca ti on s v e r s u s a ‘‘ non - b r ittl e r e s pon s e ’’ ( N BR ) , a nd c h a r ac t e r i ze t h e u s e o f d ee p b r a i n s ti m u l a ti on ( D B S ) f o r t h i s popu l a ti on 345 ( 25 . 2 ) BR : 63 . 4 ( 12 . 4 ) N BR : 68 . 1 ( 10 . 2 ) BR : 12 . 6 ( 7 . 5 ) N BR : 8 . 9 ( 5 . 2 ) 19 / 400 ( 5 . 5 % ) m e t c r it e r i a f o r BR P D T h e BR g r oup i n c l ud e d 58 % f e m a l e s , c o m p a r e d t o 29 % i n t h e N BR g r oup ( P = 0 . 008 ) BR g r oup w e r e young e r ( p = 0 . 06 ) , h a d l o w e r m ea n w e i gh t ( 63 . 5 v s . 79 . 6 , p = 0 . 001 ) , l ong e r m ea n d i s ea s e du r a ti on ( p = 0 . 003 ) , a nd h a d b ee n on l e vodop a f o r m o r e y ea r s c o m p a r e d t o N BR p a ti e n t s ( 9 . 8 v s . 5 . 9 , p = 0 . 001 ) U P D R S m o t o r s c o r e s w e r e h i gh e r ( 40 . 4 v s . 30 . 0 , p = 0 . 001 ) i n BR p a ti e n t s 63 % o f t h e BR g r oup h a d und e r gon e D B S s u r g e r y c o m p a r e d t o 18 % ( p = 0 . 001 ) . T h e r e w a s a n ov e r a ll po s iti v e b e n e ﬁ t fr o m D B S S h a r m a [ 82 ] C li n i c - b a s e d c oho r t s t udy T o e v a l u a t e r i s k f ac t o r s f o r dy s k i n e s i a 220 D y s k i n e ti c p a ti e n t s : 75 ( 8 ) N on - dy s k i n e ti c p a ti e n t s : 73 ( 8 ) D y s k i n e ti c p a ti e n t s : 8 . 6 ( 4 ) N on - dy s k i n e ti c p a ti e n t s : 5 . 3 ( 3 . 5 ) D y s k i n e ti c p a ti e n t s r ece i v e d h i gh e r d a il y do s e o f l e vodop a D y s k i n e ti c p a ti e n t s h a d l o s t w e i gh t du r i ng t h e c ou r s e o f t h e d i s ea s e ( fr o m 72 ± 15 t o 66 ± 17 kg ; p = 0 . 002 ) D y s k i n e ti c p a ti e n t s r ece i v e d h i gh e r d a il y do s e o f l e vodop a p e r k il og r a m o f body w e i gh t ( 8 . 4 ± 3 . 5 m g / kg v s . 6 . 0 ± 3 . 9 m g ; p = 0 . 003 ) W e i gh t - l o s e r s P D p a ti e n t s d e v e l op e d s i gn i ﬁ ca n tl y m o r e dy s k i n e s i a t h a n non - w e i gh t - l o s e r s ( p = 0 . 002 ) W e i gh t - l o s e r s P D p a ti e n t s d e v e l op e d m o r e dy s k i n e s i a t h a n non - w e i gh t - l o s e r s ( p = 0 . 002 ) W e i gh t l o ss a nd d a il y l e vodop a do s e p e r k il og r a m o f body w e i gh t w e r e t h e on l y s i gn i ﬁ ca n t p r e d i c t o r s f o r dy s k i n e s i a i n a dd iti on t o d i s ea s e du r a ti on S h a r m a [ 83 ] P oo l e d d a t a fr o m 056 - S t udy ( r a ndo m i ze d , doub l e b li nd s t udy ) a nd R E A L - P ET S t udy ( r a ndo m i ze d , doub l e b li nd s t udy ) T o e v a l u a t e t h e r e l a ti on s h i p b e t w ee n l e vodop a do s e p e r k il og r a m body w e i gh t a nd dy s k i n e s i a i n P D 263 ( 65 ) M e n : 62 ( 9 ) W o m e n : 62 ( 8 ) M e n : 23 ( 20 ) W o m e n : 26 ( 31 ) M e n h a d h i gh e r body w e i gh t t h a n w o m e n ( 78 . 6 ± 11 v e r s u s 65 . 9 ± 11 kg , p \ 0 . 001 ) , r ece i v e d h i gh e r l e vodop a do s e ( 640 ± 388 m g v e r s u s 429 ± 278 m g , p \ 0 . 001 ) a nd l e vodop a do s e p e r k il og r a m body w e i gh t ( 8 . 3 ± 5 m g v e r s u s 6 . 6 ± 4 m g , p \ 0 . 01 ) D y s k i n e ti c p a ti e n t s r ece i v e d h i gh e r l e vodop a do s e ( r e s p ec ti v e l y p 0 . 01 a nd p 0 . 003 ) a nd do s e p e r k il og r a m body w e i gh t ( r e s p ec ti v e l y p = 0 . 006 a nd p \ 0 . 01 ) L e vodop a do s e p e r k il og r a m body w e i gh t a nd young e r a g e w e r e t h e m o s t i m po r t a n t p r e d i c t o r f o r dy s k i n e s i a J Neurol ( 2017 ) 264 : 1583 – 1607 1597 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s U m e h [ 77 ] N I ND S N ET - P D T e r m S t udy - 1 R a ndo m i ze d , m u lti ce n t e r , doub l e b li nd s t udy ( 45 s it e s i n t h e U S a nd C a n a d a ) T o e v a l u a t e t h e po ss i b l e s e x d i ff e r e n ce s i n t h e t yp e o f dop a m i n e r g i c m e d i ca ti on u s e d a nd LE DD i n ea r l y P D 1 . 741 ( 64 . 5 ) 61 . 8 ( NA ) \ 5 T h e r e w e r e no t s t a ti s ti ca ll y d i ff e r e n ce s i n t h e p r opo r ti on s o f t yp e o f dop a m i n e r g i c m e d i ca ti on b e t w ee n m e n a nd w o m e n w it h ea r l y P D A s m a ll bu t s t a ti s ti ca ll y s i gn i ﬁ ca n t d i ff e r e n ce w a s ob s e r v e d i n t h e m e d i a n un a d j u s t e d LE DD a t b a s e li n e b e t w ee n w o m e n ( 300 m g ) a nd m e n ( 325 m g ) , bu t t h i s w a s no t ob s e r v e d a f t e r c on t r o lli ng f o r d i s ea s e du r a ti on , d i s ea s e s e v e r it y , a nd body w e i gh t F : M ( % ) t r ea t m e n t r a ti o s : L e vodop a a l on e 28 % : 29 . 6 % ; dop a m i n e a gon i s t a l on e 27 % ; 26 . 4 % ; L e vodop a p l u s dop a m i n e - a gon i s t 19 . 3 % : 17 . 9 % r e s p ec ti v e l y D i ff e r e n ce s i n m a n a g e m e n t : s u r g i ca l t r ea t m e n t A cc o ll a [ 99 ] R e t r o s p ec ti v e c oho r t s t udy ( I t a l y ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n s u r g e r y f o r P D 38 ( 57 . 8 ) W o m e n : 60 . 1 ( 8 . 5 ) M e n : 59 . 7 ( 7 ) W o m e n : 13 . 5 ( 3 . 4 ) M e n : 14 . 7 ( 5 . 8 ) B e f o r e s u r g e r y , w o m e n h a d m o r e dy s k i n e s i a t h a n m e n A f t e r s u r g e r y , b r a dyk i n e s i a r e s pond e d l e ss bu t ac ti v iti e s o f d a il y li v i ng i m p r ov e d m o r e i n w o m e n W illi s [ 92 ] R e t r o s p ec ti v e c oho r t s t udy ( U S A ) T o i d e n t i f y s o c i od e m og r a ph i c , c li n i ca l , a nd phy s i c i a n / p r ac ti c e f ac t o r s a ss o c i a t e d w it h D B S [ 650 . 000 M e d i ca r e b e n e ﬁ c i a r i e s NA NA B l ac k ( AO R : 0 . 20 , 95 % C I 0 . 16 – 0 . 25 ) a nd A s i a n ( AO R : 0 . 55 , 95 % C I 0 . 44 – 0 . 70 ) w e r e c on s i d e r a b l y l e ss li k e l y t o r ece i v e D B S t h a n w h it e p a ti e n t s W o m e n ( AO R : 0 . 79 , 95 % C I 0 . 75 – 0 . 83 ) a l s o h a d l o w e r odd s o f r ece i v i ng D B S c o m p a r e d w it h m e n B e n e ﬁ c i a r i e s t r ea t e d i n m i no r it y - s e r v i ng P D p r ac ti ce s w e r e l e ss li k e l y t o r ece i v e D B S , r e g a r d l e ss o f i nd i v i du a l r ace ( AO R : 0 . 76 , 95 % C I 0 . 66 – 0 . 87 ) C h a n [ 91 ] R e t r o s p ec ti v e c oho r t s t udy ( U S A ) T o e x a m i n e D B S u s e i n P D t o d e t e r m i n e w h i c h f ac t o r s , a m ong a v a r i e t y o f d e m og r a ph i c , c li n i ca l , a nd s o c i o ec ono m i c v a r i a b l e s , d r i v e D B S u s e i n t h e U n it e d S t a t e s 2 . 408 . 302 P D d i s c h a r g e s fr o m 2002 t o 2009 o f w ho m 18 . 312 o f t h e s e d i s c h a r g e s w e r e f o r D B S P D : 77 . 53 ( 13 . 19 ) P D w it h D B S : 63 . 66 ( 11 . 3 0 ) A fr i ca n A m e r i ca n w it h P D : 75 . 86 ( 13 . 5 ) NA Y oung e r a g e , m a l e s e x , i n c r ea s i ng i n c o m e qu a r til e o f p a ti e n t z i p c od e , l a r g e ho s p it a l s , t eac h i ng ho s p it a l s , u r b a n s e tti ng , ho s p it a l s w it h h i gh e r nu m b e r o f a nnu a l d i s c h a r g e s f o r P D , a nd i n c r ea s e d c oun t y w i d e d e n s it y o f n e u r o l og i s t s ( P \ 0 . 05 ) p r e d i c t e d u s e o f D B S i n P D P r e d i c t o r s o f nonu s e i n c l ud e d A fr i ca n A m e r i ca n r ace ( p \ 0 . 001 ) , M e d i ca i d u s e ( p \ 0 . 001 ) , a nd i n c r ea s i ng c o m o r b i d it y s c o r e ( p \ 0 . 001 ) C h a nd r a n [ 96 ] C li n i c - b a s e d c oho r t s t udy ( I nd i a ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n s u r g e r y f o r P D 51 ( 62 . 7 ) W o m e n : 54 . 5 ( 10 . 7 ) M e n : 55 . 8 ( 10 . 7 ) W o m e n : 10 . 1 ( 4 . 6 ) M e n : 11 . 1 ( 5 . 8 ) W o m e n p r e s e n t e d l o w e r do s e s o f d r ug s ( p = 0 . 03 ) , w o r s e e m o ti on a l s c o r e s i n P DQ L ( p = 0 . 01 ) a nd w o r s e d e p r e ss i on ( p = 0 . 03 ) b e f o r e s u r g e r y T h e r e w a s no g e nd e r d i ff e r e n ce i n t h e s u r g i ca l ou t c o m e , e x ce p t a l e ss e r r e du c ti on o f dop a m i n e r g i c d r ug s i n w o m e n C h i ou [ 98 ] R e t r o s p ec ti v e s t udy ( T a i w a n ) T o i nv e s ti g a t e g e nd e r - r e l a t e d f ac t o r i n D B S f o r P D 72 ( 66 . 6 ) 61 . 1 ( 2 . 3 ) 7 . 9 ( 0 . 9 ) B e f o r e s u r g e r y t h e r e w o m e n p r e s e n t e d w o r s e c ogn iti on a nd b e tt e r r e s pon s e t o l e vodop a T h e r e w a s no g e nd e r d i ff e r e n ce i n t h e s u r g i ca l ou t c o m e 1598 J Neurol ( 2017 ) 264 : 1583 – 1607 123 T a b l e 1 c on ti nu e d S t udy T yp e o f s t udy ( c oun t r y ) A i m ( s ) o f t h e s t udy N o . o f P D p a ti e n t s ( M e n , % ) A g e o f P D p a ti e n t s , * y ea r s D i s ea s e du r a ti on , * y ea r s M a i n ﬁ nd i ng s H a m b e r g [ 94 ] C li n i c - b a s e d c oho r t i n t e r v i e w ( S w e d e n ) T o i nv e s ti g a t e t h e d ec i s i on - m a k i ng p r o ce ss t o und e r go D B S f r o m t h e p a ti e n t ’ s p e r s p ec ti v e , a nd e xp l o r e a ny g e nd e r p a tt e r n s i n t h e p a r ti c i p a n t s ’ d ec i s i on - m a k i ng 39 ( 74 ) 64 . 1 ( 8 . 2 ) NA T h r ee d i ff e r e n t a pp r o ac h e s t o D B S w e r e i d e n ti ﬁ e d a m ong t h e p a ti e n t s : ( 1 ) ‘ T a k i ng o w n i n iti a ti v e ’ , i n c l ud e d 48 % o f t h e p a ti e n t s a nd i m p li e d t h a t t h e p a ti e n t s ’ o w n i n iti a ti v e s a nd a r gu m e n t s h a d b ee n c r u c i a l f o r h a v i ng s u r g e r y ; ( 2 ) ‘ A g r ee i ng w h e n o ff e r e d ’ , a nd acce p ti ng D B S w h e n s ugg e s t e d by do c t o r s e m b r ace d 43 % ; ( 3 ) ‘ H e s it a ti ng a nd w a iti ng ’ i n c l ud e d \ 10 % o f t h e p a ti e n t s M o s t o f t h e m e n w e r e e it h e r ‘ t a k i ng o w n i n iti a ti v e ’ o r ‘ a g r ee i ng w h e n o ff e r e d ’ . T h e 11 w o m e n w e r e e v e n l y d i s t r i bu t e d i n a ll t h r ee a pp r o ac h e s A m ong t h e i n t e r v i e w e d , m o r e w o m e n t h a n m e n e xp r e ss e d s t r ong f ea r o f c o m p li ca ti on s a nd m o r e w o m e n c on s u lt e d fr i e nd s a nd r e l a ti v e s p r i o r t o d ec i d i ng a bou t D B S A t ti m e f o r s u r g e r y t e n m e n bu t no w o m a n w e r e p r o f e ss i on a ll y ac ti v e H a r i z [ 95 ] C li n i c - b a s e d c oho r t s t udy ( S w e d e n ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n s u r g e r y f o r P D 46 ( 63 ) W o m e n : 65 . 8 ( 8 . 1 ) M e n : 65 . 7 ( 9 . 0 ) W o m e n : 15 . 1 ( 5 . 8 ) M e n : 10 . 2 ( 5 . 6 ) A t s u r g e r y , w o m e n h a d a s i gn i ﬁ ca n tl y l ong e r du r a ti on o f d i s ea s e t h a n m e n , h i gh e r H o e hn a nd Y a h r s ca l e a nd w o r s e s c o r e s on U P D R S p a r t s II – I V F o ll o w i ng s u r g e r y , bo t h m e n a nd w o m e n s ho w e d i m p r ov e m e n t , bu t w o m e n e xp e r i e n ce d g r ea t e r b e n e ﬁ t t h a n m e n i n ac ti v iti e s o f d a il y li v i ng , i n e m o ti on s , a nd i n s o c i a l li f e H a r i z [ 97 ] C li n i c - b a s e d c oho r t s t udy ( S w e d e n ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n s u r g e r y f o r P D 49 ( 63 . 2 ) W o m e n : 57 . 6 ( 6 . 6 ) M e n : 57 . 7 ( 7 . 8 ) W o m e n : 12 . 1 ( 5 . 3 ) M e n : 12 . 7 ( 6 . 2 ) A t s u r g e r y , w o m e n h a d l o w e r do s e s o f m e d i ca ti on s , e xp e r i e n ce d m o r e d i s a b ilit y du e t o dy s k i n e s i a a nd m ob ilit y F o ll o w i ng s u r g e r y , bo t h m e n a nd w o m e n s ho w e d i m p r ov e m e n t , bu t w o m e n e xp e r i e n ce d g r ea t e r b e n e ﬁ t t h a n m e n i n ac ti v iti e s o f d a il y li v i ng a nd qu a lit y o f li f e R o m it o [ 100 ] C li n i c - b a s e d c oho r t ( I t a l y ) T o i nv e s ti g a t e g e nd e r d i ff e r e n ce s i n D B S f o r P D 20 ( 55 ) 56 . 4 ( 6 . 9 ) 14 . 3 ( 6 . 2 ) B e f o r e s u r g e r y , t h e r e w e r e no g e nd e r d i ff e r e n ce s A f t e r s u r g e r y , t h e r e w a s a h i gh e r m o t o r r e s pon s e a f t e r 1 - y ea r , bu t no t a f t e r 3 - a nd 5 - y ea r f o ll o w up i n m e n W o m e n h a d m o r e p e r s i s t e n t a dv e r s e e v e n t s c o m p a r e d t o m e n S ce l z o [ 101 ] C li n i c - b a s e d c oho r t ( M u lti ce n t r i c , I n t e r n a ti on a l ) T o d e s c r i b e r i s k a nd m a n a g e m e n t o f p r e gn a n c y a nd d e li v e r y du r i ng t r ea t m e n t w it h D B S 11 w o m e n , o f w ho m 3 w it h P D NA NA W it h t h e e x ce p ti on o f on e a bo r ti on , a ll p r e gn a n c i e s a nd d e li v e r i e s w e r e un e v e n t f u l * D a t a a r e e x p r e ss e d i n m ea n ( s t a nd a r d d e v i a ti on ) AO R , a d j u s t e d odd s r a ti o ; AU C , a r ea und e r t h e c u r v e ; BR , b r ittl e r e s pon s e ; C I , c on ﬁ d e n ce i n t e r v a l ; DA T A T O P , D e p r e ny l a n d T o c oph e r o l A n ti ox i d a ti v e T h e r a py o f P a r k i n s on i s m ; D B S , d ee p b r a i n s ti m u l a ti on ; D S M - I V , d i a gno s ti c a nd s t a ti s ti ca l m a nu a l o f t h e A m e r i ca n P s y c h i a t r i c A ss o c i a ti on — F ou r t h E d iti on ; F , f e m a l e ; H & Y , H o e hn & Y a h r s t a g e ; H C , h ea lt hy c on t r o l s ; H R , H aza r d r a ti o ; LE DD , l e vodop a e qu i v a l e n t d a il y do s e ; L I D , l e vodop a - i ndu ce d dy s k i n e s i a ; M , m a l e ; MM S E , M i n i M e n t a l S t a t e E x a m i n a ti on ; M o C A , M on t r ea l C ogn iti v e A ss e ss m e n t b a tt e r y ; NA , no t a pp li ca b l e ; N B R , non - b r ittl e r e s pon s e ; N M S , non m o t o r s y m p t o m s ; N M SS , N on - M o t o r S y m p t o m s S ca l e ; O R , O dd s R a ti o ; P D , P a r k i n s on ’ s d i s ea s e ; P DD , P a r k i n s on ’ s d i s ea s e w it h d e m e n ti a ; P I GD , po s t u r a l i n s t a b ilit y a nd g a it d i s o r d e r s ; PP X , p r a m i p e xo l e ; P R O P A R K , P R O ﬁ li ng P A R K i n s on ’ s d i s ea s e ; PP M I , P a r k i n s o n ’ s P r og r e ss i on M a r k e r s I n iti a ti v e ; RB D , R E M b e h a v i o r d i s o r d e r ; RR , r e l a ti v e r i s k ; S C O P A - AU T , S c l ae f o r O u t c o m e i n P a r k i n s on D i s ea s e – A u t ono m i c ; S C O P A - C OG , S ca l e f o r O u t c o m e o f P a r k i n s on D i s ea s e - C ogn iti on ; U P D R S , U n i ﬁ e d P a r k i n s on ’ s d i s ea s e r a ti ng s ca l e ; U PS I T , U n i v e r s it y o f P e nn s y l v a n i a S m e ll I d e n ti ﬁ ca ti on t e s t , W OQ - 19 , t h e 19 - it e m W ea r i ng o ff Q u e s ti onn a i r e J Neurol ( 2017 ) 264 : 1583 – 1607 1599 123 to the estrogens status [ 13 , 14 ] . Indeed , gender differences in PD presentation may be attributable to biological fac - tors ; however , health - care seeking behavior should not be overlooked [ 15 ] . A study evaluating tertiary care referral in PD showed that the expected duration from onset to the movement disorders specialist visit for women was 61 % greater than for men ( p = 0 . 003 ) [ 16 ] . The effect of gender remained signiﬁcant when adjusting the model for disease severity and historical features ( age of onset and family PD history ) and supported a referral delay in women irre - spective of disease features [ 16 ] . Yet , once the disease has started , evidence reports shorter time to develop wearing off and dyskinesia in women than in men , arguing against the theory of the protective effect of estrogens [ 17 – 19 ] . According to a cross - sectional study enrolling 617 PD patients , the prevalence of wearing off was higher in women ( 72 . 5 % versus 64 % , p = 0 . 034 ) with female gender conferring an increased risk for wearing off equal to 80 . 1 % [ 19 ] . Con - ﬁrming previous ﬁndings [ 20 ] , a prospective , population - based study on 189 de novo , PD patients showed that gender is the most important independent predictor of levodopa - induced dyskinesia , with an almost threefold increased risk in women compared to men , irrespective of body weight [ 18 , 21 ] . As a matter of fact , along with younger age of onset , female gender has been associated with a shorter time to occurrence of levodopa - induced dyskinesia ( Hazard Ratio = 1 . 82 ; 95 % CI 1 . 14 – 2 . 89 , p = 0 . 011 ) with a median time to dyskinesia of 4 years in women and 6 years in men [ 22 ] . Yet , the role of gender in determining either a more benign or aggressive motor disease course is far to be clear . Non - motor symptoms Although methodological issues ( as the use of different scales ) limit the comparison of the available data , the majority of studies suggest the existence of gender - related differences in non - motor symptoms ( NMS ) prevalence in PD . As a matter of fact , several studies showed that feel - ings of nervousness and sadness , constipation , restless legs and pain are more common in women , while daytime sleepiness , dribbling saliva , reduced interest in sex and problems having sex are more prevalent in men [ 23 – 27 ] . Indeed , since it is known that dopaminergic treatment may affect several NMS differently [ 28 ] , as a major limitation these studies only included patients on dopaminergic treatment . By administering the Non - Motor Symptoms Questionnaire to 200 early , drug - native PD patients and 93 age - and sex - matched healthy controls , we were able to show PD - speciﬁc gender differences in NMS , irrespective of disease progression and dopaminergic therapy [ 29 ] . Our study showed that men with PD complained more frequently about dribbling , sadness / blues , loss of interest , anxiety , acting during dreams , and taste / smelling difﬁcul - ties compared to healthy control men , while female PD patients reported more frequently loss of interest and anxiety compared to healthy control women [ 29 ] . In con - trast with previous data on treated PD patients [ 23 , 24 , 30 ] , female PD patients did not present higher prevalence of mood symptoms compared to male PD patients . Compar - ison with healthy controls showed that several NMS clas - sically present in the promotor phase and pointing to subjects with subsequent development of PD in large population studies ( i . e . , sadness / blues , acting out during dreams , taste / smelling difﬁculties ) [ 31 – 33 ] are more fre - quent in male than in female patients [ 29 ] . Further sup - porting the importance of these ﬁndings , Liu et al . described a combination of NMS that can best differentiate PD from controls [ 34 ] . Remarkably , in both men and women , poor olfaction was the most powerful NMS pre - dicting PD diagnosis , followed by the Montreal Cognitive Assessment battery score , but , once again , gender made a difference , since dysautonomia was a predictor of PD diagnosis only in men , while REM sleep behavior disorder only in women [ 34 ] . The large sample size and the use of multiple detailed NMS assessment tools further corroborate the importance of these ﬁndings [ 34 ] ( Table 1 ) . Yet , the role of gender in the response of NMS to dopamine replacement therapy was not established . Sub - sequently , we conducted a 2 - year prospective assessment of gender - related differences in the burden of NMS before and after starting dopaminergic therapy showing that sad - ness / blues presented a signiﬁcant percentage reduction compared to baseline in both sexes , while urgency , daytime sleepiness , weight gain and increase in sex drive presented a signiﬁcant percentage increase only in men possibly in relation to both disease progression and dopaminergic treatment [ 35 ] . Conﬁrming previous ﬁndings [ 27 , 36 ] , male gender was a risk factor for developing both dribbling ( odds ratio = 10 . 29 ) and nocturia ( odds ratio = 9 . 90 ) , irrespective of therapy and clinical features [ 35 ] . However , as the disease progresses , NMS appear in the form of non - motor ﬂuctuations more frequently in women than in men . By administering the 19 - item Wearing off Questionnaire to 47 PD patients ( M : F = 31 : 16 ) after 4 years since the start of dopaminergic treatment , we showed that mood - related non - motor ﬂuctuations ( i . e . , anxiety , mood changes and pain ) were more prevalent in women [ 37 ] . These ﬁndings possibly account for the higher prevalence of mood - related NMS reported by women in studies including PD patients on dopaminergic treatment and with different stages of disease [ 26 , 27 ] . Strikingly , in our study no gender differences were detected in either dopaminergic or antidepressants / benzodiazepines intake , despite the higher frequency of non - motor ﬂuctuations 1600 J Neurol ( 2017 ) 264 : 1583 – 1607 123 evidenced in women , suggesting that non - motor ﬂuctua - tions in women remain mostly underestimated and under - treated [ 37 ] . Regarding cognition , several studies suggest that , as opposite to the female prevalence of dementia ( e . g . , Alz - heimer’s disease ) in the general population [ 4 ] , male gen - der is a robust risk factor for development of cognitive impairment and dementia in PD [ 38 – 40 ] . Interestingly , recent data suggest that dementia prevalence in women with PD began to increase steadily after the age of 65 years , reaching male estimates only after 80 years of age [ 41 ] . Thus , mirroring the course of motor symptoms , PD NMS and cognitive disturbances start with a more benign phenotype in women compared to men , but then present a steadily progressive worsening as disease pro - gresses . Indeed , NMS develop differently in women and men ; taste and smell difﬁculties are reported mainly in men and anxiety in women , respectively , suggesting that the prodromal stage of PD proceeds differently in both sexes [ 42 ] . In turn , NMS may be useful to differentiate patients at PD risk if gender is included as an important variable . However , it has to be considered that pre - existing sex differences such as in olfaction might be further exacer - bated by the onset of PD . Biomarkers Despite few data suggested gender differences for other biomarkers in PD [ 43 – 46 ] , the most robust evidence is available for urate . Previous prospective and case – control studies showed that lower urate concentrations predicted PD prognosis and were inversely associated with disease severity in men but not in women [ 47 – 50 ] . In a postmortem study , urate levels in cortical and striatal tissue were lower in PD than in controls in men only [ 51 ] . Intriguingly , more recent data further expand the relationship between urate and gender in PD . With a nested case – control study based on 90 . 214 participants of three ongoing US cohorts , Gao et al . obtained data for 388 new PD cases ( 52 % men ) and 1 . 267 matched healthy controls ( 35 % men ) [ 52 ] . Logistic regression analysis showed that men , but not women , with higher urate concentrations had a lower future risk of developing PD , suggesting that urate can be protective against PD risk or could slow disease progression during the preclinical stage of the disease in men only [ 52 ] . In addition , by performing a meta - analysis on urate and PD risk in men and women separately , the authors pooled their data with additional 325 incident PD cases and further conﬁrmed this gender difference [ 52 ] . The pathophysio - logical explanations underlying such gender speciﬁcity of urate in determining PD risk remain speculative . Other factors might offset the potential neuroprotective effects of urate in women , or estrogens may predominate in deter - mining the lower risk of PD among women [ 52 ] . On a practical ground , these data , combined with the evidence on NMS , further support the need for gender - based strategies involving clinical and serum biomarkers to identify prodromal PD cases [ 34 ] . Genetics In this section , the available evidence on gender differ - ences in genes determining PD susceptibility is examined , while the large body of pharmacogenetic data was left out of the scope of this review . While variable evidence suggests that speciﬁc poly - morphisms’ expression may be inﬂuenced by gender [ 53 - 66 ) , a number of studies support a role for LRRK2 status in either reverting or balancing the gender distribution in PD [ 67 – 71 ] . Mutations in the LRRK2 gene are among the most common genetic factors causing PD worldwide and par - ticularly common in selected populations ( e . g . , Ashkenazi Jews and North African Berbers ) [ 69 ] . LRRK2 mutations are inherited with an autosomal dominant pattern with incomplete and age - related penetrance . As a matter of fact , asymptomatic LRRK2 carriers represent the ideal setting to study prodromal PD [ 72 ] . Several studies suggest that PD LRRK2 - associated PD patients are more likely women , as opposite to the gender distribution in glucocerebrosidase ( GBA ) - associated PD which mirrors the prevalence ratios in the general population [ 73 ] . Although a recent meta - analysis rebuts this ﬁnding and shows a 1 : 1 male to female ratio in LRRK2 - associated PD [ 74 ] , the factors associated with the possible rebalancing of the male to female ratio in LRRK2 - associated PD compared to idiopathic PD are unknown . Indeed , there is a need for studies evaluating the effect of gender on both genetic and environmental factors determining the PD risk . Gender differences in Parkinson’s disease management Pharmacological treatment Although therapeutic recommendations for PD take into account age , motor disability as well as the presence of disease - related complications ( i . e . , motor ﬂuctuations and neuropsychiatric complications ) , to date no gender - ori - ented advice is available [ 75 , 76 ] . Yet , gender is one of the pivotal determinants of development of motor and non - motor ﬂuctuations as well as dyskinesia ( see above ) [ 17 – 22 , 37 ] . In addition , no ad hoc prospective studies have been conducted so far and the available evidence on the topic can be inferred from either retrospective studies or J Neurol ( 2017 ) 264 : 1583 – 1607 1601 123 the subanalysis of prospective data collected for different objectives . As for the type of dopaminergic medication , evidence shows similar treatments assigned to men and women with PD , with no gender preference [ 77 , 78 ] . As such , the NINDS NET - PD study , including data from 1 . 741 PD patients , reports similar gender ratios for treatment with levodopa alone , dopamine agonist alone or levodopa plus dopamine agonist [ 77 ] . Though , as for medication dosage , several studies demonstrate that men with PD are medi - cated with higher doses of either oral or infusional treat - ments , as evaluated with the levodopa equivalent daily dose ( LEDD ) [ 78 – 81 ] . However , when body weight is added as a covariate , the gender differences in LEDD recedes [ 77 ] , suggesting the core of the matter might be the dosage adjustment according to the body weight [ 82 , 83 ] . As opposite to dopamine agonists [ 84 ] , several studies have demonstrated that levodopa pharmacokinetics is signiﬁ - cantly affected by the body weight with an inverse corre - lation between the plasmatic levodopa concentration ( i . e . , the area under the curve , AUC ) and body weight , which is lower in women on average . Arabia et al . observed a lower body weight ( 65 . 3 kg versus 73 . 9 kg , p \ 0 . 001 ) with greater levodopa AUC in women with PD ( 6 . 45 l mol / l h among women versus 4 . 94 l mol / l h among men , p = 0 . 002 ) and reported an inverse correlation between AUC and T 1 / 2 ( i . e . , half - life ) and body weight ( respec - tively , p \ 0 . 001 and p = 0 . 001 ) [ 85 ] . However , further evidence suggest that women present greater levodopa bioavailability with higher mean AUC ( 42 . 3 ± 7 mg ver - sus 23 . 3 ± 7 . 3 ; p \ 0 . 0001 ) and higher mean C max ( 1388 ± 42 mg versus 800 ± 33 mg ; p \ 0 . 001 ) after administration of 100 mg of levodopa , irrespective of body weight [ 84 , 86 ] . In addition , women display lower levo - dopa clearance levels , further justifying the greater levo - dopa bioavailability [ 87 ] . Recent evidence delineated the features characterizing a subgroup of patients reporting a ‘‘brittle response’’ to levodopa , deﬁned as the presence of highly disabling dyskinesia after small doses ( i . e . , 100 mg or less per dose ) [ 88 ] . Those extremely sensitive subjects are mainly women ( 58 % ) with lower body weight and body mass index ( 63 . 5 versus 79 . 6 kg , p \ 0 . 001 and 22 . 3 ver - sus 26 . 5 , p \ 0 . 001 , respectively ) , longer disease duration and much many years on levodopa , but with lower dosage ( 12 . 6 versus 8 . 9 years , p = 0 . 003 and 9 . 8 versus 5 . 9 years , p \ 0 . 001 , respectively ) , compared to patients without a ‘‘brittle response’’ [ 88 ] . Although this study suggests new insight into the phenomenology of the response to levo - dopa , the genetic background of the patients with ‘‘brittle response’’ is overlooked [ 88 ] . Indeed , the lower female body weight alone cannot entirely account for the gender discrepancy in development of levodopa - related complication . PD is associated with a profound alteration in central control of energy metabolism determining continuous changes in body weight and com - position and energy expenditure in relation to both disease progression and type of treatment [ 89 ] . Furthermore , genetic polymorphisms may also have a role in modulating the dyskinesia risk ( e . g . , DRD2 polymorphism has a pro - tective effect against dyskinesia development only in men [ 20 ] ) . Intriguingly , not all PD patients convert to a ‘‘brittle response’’ , suggesting this subgroup might have peculiar features placing them at risk for maladaptive plastic responses to levodopa [ 89 ] . There is a need for prospective ad hoc studies to clarify why women with PD have higher rates of levodopa - related complications and are at risk for presenting a ‘‘brittle response’’ to levodopa . Surgical treatment Several randomized clinical trials have shown bilateral subthalamic nucleus deep brain stimulation ( DBS ) to be effective in PD patients with motor ﬂuctuations [ 90 ] . Notwithstanding , this option is underused in certain groups of patients , such as ethnic minorities and low - level socioeconomic status subjects [ 91 , 92 ] . Strikingly , in spite of the higher risk of developing dyskinesia and motor ﬂuctuations in women , female gender has been repetitively associated with lower utilization of DBS in PD [ 91 – 93 ] . The observation that in the western world the proportion of male patients who receive DBS exceeds the usual male / female predominance of PD might have several explana - tions as doctors’ attitude and potential gender bias in proposing DBS , stronger fear for surgical risks among women or more initiative in men who autonomously demand for DBS [ 93 , 94 ] . However , the lack of large ad hoc prospective studies prevents us from drawing conclu - sions on the reasons for the gender discrepancy in DBS access [ 92 , 93 ] . As a matter of fact , women with PD per - form DBS later than men displaying longer disease dura - tion , more severe disease and much more dyskinesia at the time of surgery [ 95 ] . Yet , DBS provides beneﬁt in both genders determining equal clinical improvement and reduction in medications with even greater impact on activities of daily living and quality of life in women [ 96 – 100 ] . Postponing DBS in PD women might have a detrimental impact on life planning . Recent reports demonstrate that , due to its efﬁcacy on psychomotor status and treatment reduction , DBS is a safe option in the management of young PD women who wish to become pregnant [ 101 ] . However , there is the need to deﬁne strategies to prevent and control any worsening of clinical conditions during pregnancy and to consider device - related options ( i . e . , rechargeable battery to avoid battery replacement and subclavicular placement instead of abdominal ) in women who plan to become pregnant [ 100 ] . 1602 J Neurol ( 2017 ) 264 : 1583 – 1607 123 Finally , DBS is a valid approach to relieve disability in patients with ‘‘brittle response’’ to levodopa ( see above ) , who are mostly women [ 88 ] . The role of estrogens Estrogens are likely contributors to gender differences in PD [ 102 – 104 ] . Although conﬂicting data are available , evidence would suggest a link between longer estrogen exposure during lifetime and both the decreased PD risk and milder features at onset in women [ 105 – 119 ] . Most women develop PD after menopause , further suggesting estrogen withdrawal has a role in disease pathogenesis [ 9 , 13 , 14 ] . Accordingly , preclinical evidence shows that estrogens are protective against dopaminergic damage . Animal models with estrogens deprivation show dopaminergic neuron loss , altered dopaminergic metabo - lism and transporter uptake , which can be partially reversed by the administration of exogenous estrogens [ 102 – 104 ] . A large body of evidence shows that estradiol and related compounds exert neuromodulatory and neuropro - tective activities in the striatum and substantia nigra through several intracellular mechanisms that ultimately decrease apoptosis of neurons . In addition to these signal cascade effects , estrogens might impact PD pathogenesis via their inﬂuence on mitochondrial function and response to oxidative stress . Evidence demonstrates that estrogens might also prevent Lewy body deposition through speciﬁc alpha - synuclein anti - aggregation and ﬁbril destabilization properties [ 102 – 104 ] . However , in contrast with the large body of preclinical evidence [ 104 ] , a spoonful of studies on humans are available on the clinical effects of estrogens in PD . A small pilot study showed that estrogen replacement therapy in non - parkinsonian women increases putaminal dopamine active transporter as measured with TRODAT SPECT scan [ 120 ] . Although small trials have demonstrated mild efﬁ - cacy of low - dose estrogens in improving motor disability and motor ﬂuctuations in post - menopausal women [ 121 – 125 ] , estrogens have not been further tested in larger cohort . Although there is an increasing interest of the research community in testing the disease - modifying effect of estrogens in different neurological conditions [ 126 ] , clinical trials of estrogen face unique challenges possibly explaining the lack of data in larger PD cohort [ 123 ] . Estrogen is an endogenous compound with levels that naturally ﬂuctuate throughout the lifecycle . Estrogen’s effects are widespread in and outside the brain and Fig . 1 Synoptic diagram showing gender difference in early ( left side ) and advanced ( right side ) PD . As for early PD , women have lower prevalence and incidence , slightly higher age at onset , higher tremor dominance and striatal uptake compared to men , justifying the deﬁnition of ‘‘more benign phenotype’’ . As for advanced PD , women have more motor and non - motor ﬂuctuations as well as dyskinesia and reduced access to DBS , thus challenging the deﬁnition of ‘‘more benign phenotype’’ . DBS deep brain stimulation , PD Parkinson’s disease J Neurol ( 2017 ) 264 : 1583 – 1607 1603 123 conventional study designs have difﬁculty assessing com - plex variables including variability in endogenous / exoge - nous estrogen exposure , and the interface between hormonal changes and the onset / progression of a chronic disease . Ultimately , as chronic estrogen exposure is asso - ciated with increased risk of breast cancer and coronary heart disease , risks may exceed beneﬁts [ 127 ] . Conclusions Here , we gathered evidence demonstrating the existence of gender differences in PD clinical phenotype , biomarkers and therapeutic management . Still , much work needs to be done to better understand the interaction between gender and genetics in determining the PD risk and clinical fea - tures . Several data demonstrate that PD in women starts with a more benign phenotype , likely due to the effect of estrogens . However , as the disease progresses , women are at higher risk of developing highly disabling treatment - related complications , such as motor and non - motor ﬂuc - tuations as well as dyskinesia , compared with men . In addition , women have lower chances of receiving effective treatment for PD as DBS ( Fig . 1 ) . Taken together these ﬁndings challenge the deﬁnition of a more benign pheno - type in women . Improving our understanding in this ﬁeld may result in implementation of strategies to identify prodromal PD cases and speed efforts to discern new directions for PD tailored treatment and management . We just got the evi - dence that gender does matter in PD [ 128 ] . It matters in many ways we did not expect . It also matters in ways we have not envisaged yet [ 1 ] . Acknowledgements This review was designed after the authors have been involved in a talk about ‘‘Gender differences in movement disorders’’ during the last meeting of the Italian LIMPE - DISMOV Academy held in Bari on May 4 – 6 , 2016 . Compliance with ethical standards Conﬂicts of interest The authors declare no ﬁnancial disclosures related to the content of this article . The authors declare no conﬂict of interest . References 1 . Institute of Medicine Board on Health Sciences Policy , Com - mittee on Understanding the Biology of Sex and Gender Dif - ferences . ( 2001 ) Exploring the biological contributions to human health : does sex matter ? In : Wizemann TM , Pardue M - L ( eds ) Institute of Medicine , Washington , DC 2 . Bellou V , Belbasis L , Tzoulaki I , Evangelou E , Ioannidis JP ( 2016 ) Environmental risk factors and Parkinson’s disease : an umbrella review of meta - analyses . Parkinsonism Relat Disord 23 : 1 – 9 3 . Mazure CM , Jones DP ( 2015 ) Twenty years and still counting : including women as participants and studying sex and gender in biomedical research . BMC Womens Health 15 : 94 4 . Mazure CM , Swendsen J ( 2016 ) Sex differences in Alzheimer’s disease and other dementias . Lancet Neurol 15 : 451 – 452 5 . Wooten GF , Currie LJ , Bovbjerg VE , Lee JK , Patrie J ( 2004 ) Are men at greater risk for Parkinson’s disease than women ? J Neurol Neurosurg Psychiatry 75 : 637 – 639 6 . Taylor KSM , Cook JA , Counsell CE ( 2007 ) Heterogeneity in male to female risk for Parkinson’s disease . J Neurol Neurosurg Psychiatry 78 : 905 – 912 7 . Burn DJ ( 2007 ) Sex and Parkinson’s disease : a word of differ - ence ? J Neurol Neurosurg Psychiatry 78 : 787 8 . Pringsheim T , Jette N , Frolkis A , Steeves TD ( 2014 ) The prevalence of Parkinson’s disease : a systematic review and meta - analysis . Mov Disord 29 : 1583 – 1590 9 . Moisan F , Kab S , Mohamed F et al ( 2015 ) Parkinson disease male - to - female ratios increase with age : French nationwide study and meta - analysis . J Neurol Neurosurg Psychiatry 87 : 952 – 957 10 . Lonneke ML de Lau , Dagmar Verbaan A , Johan Marinus A , van Hilten JJ ( 2014 ) Survival in Parkinson’s disease , Relation with motor and non - motor Features , Parkinsonism and Related Disorders 20 : 613 – 616 11 . Pinter B , Diem - Zangerl A , Wenning GK et al ( 2015 ) Mortality in Parkinson’s disease : a 38 - year follow - up study . Mov Disord 30 : 266 – 269 12 . Xu J , Gong DD , Man CF , Fan Y ( 2014 ) Parkinson’s disease and risk of mortality : meta - analysis and systematic review . Acta Neurol Scand 129 : 71 – 79 13 . Haaxma CA , Bloem BR , Borm GF et al ( 2007 ) Gender differ - ences in Parkinson’s disease . J Neurol Neurosurg Psychiatry 78 : 819 – 824 14 . Cereda E , Barichella M , Cassani E , Caccialanza R , Pezzoli G ( 2013 ) Reproductive factors and clinical features of Parkinson’s disease . Parkinsonism Related Disorders 19 : 1094 – 1099 15 . Adamson J , Ben - Shlomo Y , Chaturvedi N , Donovan J ( 2003 ) Ethnicity , socio - economic position and gender—do they affect reported health - care seeking behaviour ? Soc Sci Med 57 : 895 – 904 16 . Saunders - Pullman R , Wang C , Stanley K , Bressman SB ( 2011 ) Diagnosis and Referral Delay in Women With Parkinson’s Disease . Gend Med 8 : 209 – 217 17 . Sato K , Hatano T , Yamashiro K et al ( 2006 ) Prognosis of Parkinson’s disease : time to stage III , IV , V , and to motor ﬂuctuations . Mov Disord 21 : 1384 – 1395 18 . Bjornestad A , Forsaa EB , Pedersen KF , Tysnes OB , Larsen JP , Alves G ( 2016 ) Risk and course of motor complications in a population - based incident Parkinson’s disease cohort . Parkin - sonism Related Disorders 22 : 48 – 53 19 . Colombo D , Abbruzzese G , Antonini A et al ( 2015 ) The ‘‘Gender Factor’’ in Wearing - Off among Patients with Parkin - son’s Disease : a post Hoc analysis of DEEP study . Sci World J 787451 20 . Zappia M , Annesi G , Nicoletti G et al ( 2005 ) Sex differences in clinical and genetic determinants of levodopa peak - dose dyski - nesias in Parkinson disease : an exploratory study . Arch Neurol 62 : 601 – 605 21 . Sharma JC , Bachmann CG , Linazasoro G ( 2010 ) Classifying risk factors for dyskinesia in Parkinson’s disease . Park Relat Disord 16 : 490 – 497 22 . Hassin - Baer S , Molchadski I , Cohen OS et al ( 2011 ) Gender effect on time to levodopa - induced dyskinesias . J Neurol 258 : 2048 – 2053 23 . Leentjens AF , Dujardin K , Marsh L , Martinez - Martin P , Richard IH , Starkstein SE ( 2011 ) Symptomatology and markers of 1604 J Neurol ( 2017 ) 264 : 1583 – 1607 123 anxiety disorders in Parkinson’s disease : a cross - sectional study . Mov Disord 26 : 484 – 492 24 . Leentjens AF , Moonen AJ , Dujardin K ( 2013 ) Modeling depression in Parkinson disease : disease - speciﬁc and nonspeci - ﬁc risk factors . Neurology 81 : 1036 – 1043 25 . Szewczyk - Krolikowski K , Tomlinson P , Nithi K ( 2014 ) The inﬂuence of age and gender on motor and non - motor features of early Parkinson’s disease : initial ﬁndings from the Oxford Parkinson Disease Center ( OPDC ) discovery cohort . Parkin - sonism Relat Disord 20 : 99 – 105 26 . Solla P , Cannas A , Ibba FC ( 2012 ) Gender differences in motor and non - motor symptoms among Sardinian patients with Parkinson’s disease . J Neurol Sci 323 : 33 – 39 27 . Martinez - Martin P , Falup Pecurariu C ( 2012 ) Gender - related differences in the burden of non - motor symptoms in Parkinson’s disease . J Neurol 259 : 1639 – 1647 28 . Erro R , Picillo M , Vitale C ( 2013 ) Non - motor symptoms in early Parkinson’s disease : a 2 - years follow - up study on previously untreated patients . J Neurol Neurosurg Psychiatry 84 : 14 – 17 29 . Picillo M , Amboni M , Erro R et al ( 2013 ) Gender differences in non - motor symptoms in early , drug naı¨ve Parkinson’s disease . J Neurol 260 : 2849 – 2855 30 . Song Y , Gu Z , An J , Chan P ; Chinese Parkinson Study Group ( 2014 ) Gender differences on motor and non - motor symptoms of de novo patients with early Parkinson’s disease . Neurol Sci 35 : 1991 – 1996 31 . Shen CC , Tsai SJ , Perng CL , Kuo BI , Yang AC ( 2013 ) Risk of Parkinson disease after depression : a nationwide population - based study . Neurology 81 : 1538 – 1544 32 . Postuma RB , Gagnon JF , Bertrand JA , Ge´nier Marchand D , Montplaisir JY ( 2015 ) Parkinson risk in idiopathic REM sleep behavior disorder : preparing for neuroprotective trials . Neurol - ogy 84 : 1104 – 1113 33 . Picillo M , Pellecchia MT , Erro R et al ( 2014 ) The use of University of Pennsylvania Smell Identiﬁcation Test in the diagnosis of Parkinson’s disease in Italy . Neurol Sci 35 : 379 – 3783 34 . Liu R , Umbach DM , Peddada SD , Xu Z , Tro¨ster AI , Huang X , Chen H ( 2015 ) Potential sex differences in non motor symptoms in early drug - naive Parkinson disease . Neurology 84 : 2107 – 2115 35 . Picillo M , Erro R , Amboni M et al ( 2014 ) Gender differences in non - motor symptoms in early Parkinson’s disease : a 2 - years follow - up study on previously untreated patients . Parkinsonism Relat Disord 20 : 850 – 854 36 . Guo X , Song W , Chen K et al ( 2013 ) Gender and onset age - related features of non - motor symptoms of patients with Parkinson’s disease—a study from Southwest China . Parkin - sonism Relat Disord 19 : 961 – 965 37 . Picillo M , Palladino R , Moccia M et al ( 2016 ) Gender and non motor ﬂuctuations in Parkinson’s disease : a prospective study . Parkinsonism Relat Disord 27 : 89 – 92 38 . Uc EY , McDermott MP , Marder KS et al ( 2009 ) Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort . Neurology 73 : 1469 – 1477 39 . Anang JB , Gagnon JF , Bertrand JA et al ( 2014 ) Predictors of dementia in Parkinson disease : a prospective cohort study . Neurology 83 : 1253 – 1560 40 . Pigott K , Rick J , Xie SX et al ( 2015 ) Longitudinal study of normal cognition in Parkinson disease . Neurology 85 : 1276 – 1282 41 . Cereda E , Cilia R , Klersy C et al ( 2016 ) Dementia in Parkin - son’s disease : is male gender a risk factor ? Parkinsonism Relat Disord 26 : 67 – 72 42 . Nicoletti A , Vasta R , Mostile G et al ( 2016 ) Gender effect on non motor symptoms in parkinson’s disease : are men more at risk ? Parkinsonims Relat Disord . doi : 10 . 1016 / j . parkreldis . 2016 . 12 . 008 43 . Brighina L , Prigione A , Begni B et al ( 2010 ) Lymphomonocyte alpha - synuclein levels in aging and in Parkinson disease . Neu - robiol Aging 31 : 884 – 885 44 . Ikeda K , Nakamura Y , Kiyozuka T et al ( 2011 ) Serological proﬁles of urate , paraoxonase - 1 , ferritin and lipid in Parkinson’s disease : changes linked to disease progression . Neurodegener Dis 8 : 252 – 258 45 . Caranci G , Piscopo P , Rivabene R et al ( 2013 ) Gender differ - ences in Parkinson’s disease : focus on plasma a - synuclein . J Neural Transm 120 : 1209 – 1215 46 . Ho DH , Yi S , Seo H , Son I , Seol W ( 2014 ) Increased DJ - 1 in urine exosome of Korean males with Parkinson’s disease . Biomed Res Int 704678 47 . Schwarzschild MA , Schwid SR , Marek K et al ( 2008 ) Serum urate as a predictor of clinical and radiographic progression in Parkinson’s disease . Arch Neurol 265 : 716 – 723 48 . Ascherio A , LeWitt PA , Xu K et al ( 2009 ) Urate as a predictor of the rate of clinical decline in Parkinson disease . Arch Neurol 66 : 1460 – 1468 49 . Schwarzschild MA , Marek K , Eberly S et al ( 2011 ) Serum urate and probability of dopaminergic deﬁcit in early ‘‘Parkinson’s disease’’ . Mov Disord 26 : 1864 – 1868 50 . Jesus S , Pe´rez I , Ca´ceres - Redondo MT et al ( 2013 ) Low serum uric acid concentration in Parkinson’s disease in southern Spain . Eur J Neurol 20 : 208 – 210 51 . McFarland NR , Burdett T , Desjardins CA , Frosch MP , Sch - warzschild MA ( 2013 ) Postmortem brain levels of urate and precursors in Parkinson’s disease and related disorders . Neu - rodegener Dis 12 : 189 – 198 52 . Gao X , O’Reilly E´J , Schwarzschild MA , Ascherio A ( 2016 ) Prospective study of plasma urate and risk of Parkinson disease in men and women . Neurology 86 : 520 – 526 53 . Foltynie T , Lewis SG , Goldberg TE et al ( 2005 ) The BDNF Val66Met polymorphism has a gender speciﬁc inﬂuence on planning ability in Parkinson’s disease . J Neurol 252 : 833 – 838 54 . Gatt AP , Jones EL , Francis PT , Ballard C , Bateman JM ( 2013 ) Association of a polymorphism in mitochondrial transcription factor A ( TFAM ) with Parkinson’s disease dementia but not dementia with Lewy bodies . Neurosci Lett 557 : 177 – 180 55 . Gusdon AM , Fang F , Chen J et al ( 2015 ) Association of the mt - ND2 5178A / C polymorphism with Parkinson’s disease . Neu - rosci Lett 587 : 98 – 101 56 . Klebe S , Golmard JL , Nalls MA et al ( 2004 ) The Val158Met COMT polymorphism is a modiﬁer of the age at onset in Parkinson’s disease with a sexual dimorphism . J Neurol Neu - rosurg Psychiatry 84 : 666 – 673 57 . Lin JJ , Yueh KC , Chang CY , Chen CH , Lin SZ ( 2004 ) The homozygote AA genotype of the alpha1 - antichymotrypsin gene may confer protection against early - onset Parkinson’s disease in women . Parkinsonism Relat Disord 10 : 469 – 473 58 . Lin JJ , Chen CH , Yueh KC , Chang CY , Lin SZ ( 2006 ) A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson’s disease for females . Parkinsonism Relat Disord 12 : 9 – 13 59 . Liu RR , Zhou LL , Cheng X et al ( 2014 ) CCDC62 variant rs12817488 is associated with the risk of Parkinson’s disease in a Han Chinese population . Eur Neurol 71 : 77 – 83 60 . Mariani S , Ventriglia M , Simonelli I et al ( 2016 ) Association between sex , systemic iron variation and probability of Parkin - son’s disease . Int J Neurosci 126 : 354 – 360 61 . Palacios N , Weisskopf M , Simon K , Gao X , Schwarzschild M , Ascherio A ( 2010 ) Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson’s disease in men and women . Parkinsonism Relat Disord 16 : 370 – 375 62 . San Luciano M , Ozeliusb L , Liptonc RB , Raymonda D , Bress - man SB , Saunders - Pullman R ( 2012 ) Gender differences in the J Neurol ( 2017 ) 264 : 1583 – 1607 1605 123 IL6 - 174G [ C and ESR2 1730G [ A polymorphisms and the risk of Parkinson’s disease . Neurosci Lett 506 : 312 – 316 63 . Simunovic F , Yi M , Wang Y , Stephens R , Sonntag KC ( 2010 ) Evidence for gender - speciﬁc transcriptional proﬁles of Nigral dopamine neurons in Parkinson disease . PLoS ONE 5 : e8856 64 . Yu RL , Guo JF , Wang YQ et al ( 2015 ) The single nucleotide polymorphism Rs12817488 is associated with Parkinson’s dis - ease in the Chinese population . J Clin Neurosci 22 : 1002 – 1004 65 . Zhang P , Liu L , Huang J et al ( 2014 ) Non - SMC condensin I complex , subunit D2 gene polymorphisms are associated with Parkinson’s disease : a Han Chinese study . Genome 57 : 253 – 257 66 . Zhao J , Han X , Xue L , Zhu K , Liu H , Xie A ( 2015 ) Association of TLR4 gene polymorphisms with sporadic Parkinson’s disease in a Han Chinese population . Neurol Sci 36 : 1659 – 1665 67 . Agalliu I , San Luciano M , Mirelman A et al ( 2015 ) Higher frequency of certain cancers in LRRK2 G2019S mutation car - riers with Parkinson disease : a pooled analysis . JAMA Neurol 72 : 58 – 65 68 . Cilia R , Siri C , Rusconi D et al ( 2014 ) LRRK2 mutations in Parkinson’s disease : conﬁrmation of a gender effect in the Italian population . Parkinsonism Relat Disord 20 : 911 – 914 69 . Clark LN , Wang Y , Karlins E et al ( 2006 ) Frequency of LRRK2 mutations in early - and late - onset Parkinson disease . Neurology 67 : 1786 – 1791 70 . Orr - Urtreger A , Shifrin C , Rozovski U , Rosner S et al ( 2007 ) The LRRK2 G2019S mutation in Ashkenazi Jews with Parkin - son disease : is there a gender effect ? Neurology 69 : 1595 – 1602 71 . Saunders - Pullman R , Stanley K , San Luciano M , Barrett MJ et al ( 2011 ) Gender differences in the risk of familial parkin - sonism : beyond LRRK2 ? Neurosci Lett 496 : 125 – 128 72 . Mirelman A , Alcalay RN , Saunders - Pullman R et al ( 2015 ) Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene . Mov Disord 30 : 981 – 986 73 . Gan - Or Z , Bar - Shira AA , Mirelman A et al ( 2010 ) LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease . Neurogenetics 11 : 121 – 125 74 . Gan - Or Z , Leblond CS , Mallett V , Orr - Urtreger A , Dion PA , Rouleau G ( 2015 ) LRRK2 mutations in Parkinson disease ; a sex effect or lack thereof ? A meta - analysis . Parkinsonism Relat Disord 21 : 778 – 782 75 . Lang AE , Lees A ( 2002 ) Management of Parkinson’s Disease : an evidence - based review . Mov Disord 17 : S1 – S166 76 . Ferreira JJ , Katzenschlager R , Bloem BR et al ( 2013 ) Summary of the recommendations of the EFNS / MDS - ES review on ther - apeutic management of Parkinson’s disease . Eur J Neurol 20 : 5 – 15 77 . Umeh CC , Pe´rez A , Augustine EF et al ( 2014 ) No sex differ - ences in use of dopaminergic medication in early Parkinson disease in the US and Canada—baseline ﬁndings of a multi - center trial . PLoS One 9 : e112287 78 . Baba Y , Putzke JD , Whaley NR , Wszolek ZK , Uitti RJ ( 2005 ) Gender and the Parkinson’s disease phenotype . J Neurol 252 : 1201 – 1205 79 . Nyholm D , Karlsson E , Lundberg M , Askmark H ( 2010 ) Large differences in levodopa dose requirement in Parkinson’s disease : men use higher doses than women . Eur J Neurol 17 : 260 – 266 80 . Lubomski M , Louise Rushworth R , Lee W , Bertram KL , Wil - liams DR ( 2014 ) Sex differences in Parkinson’s disease . J Clin Neurosci 21 : 1503 – 1506 81 . Nyholm D , Constantinescu R , Holmberg B , Dizdar N , Askmark H ( 2009 ) Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom ﬂuctua - tions . Acta Neurol Scand 119 : 345 – 348 82 . Sharma JC , Macnamara L , Hasoon M , Vassallo M , Ross I ( 2006 ) Cascade of levodopa dose and weight - related dyskinesia in Parkinson’s disease ( LD – WD - PD cascade ) . Parkinsonism Relat Disord 12 : 499 – 505 83 . Sharma JC , Ross IN , Rascol O , Brooks D ( 2008 ) Relationship between weight , levodopa and dyskinesia : the signiﬁcance of levodopa dose per kilogram body weight . Eur J Neurol 15 : 493 – 496 84 . Kompoliti K , Adler CH , Raman R et al ( 2002 ) Gender and pramipexole effects on levodopa pharmacokinetics and phar - macodynamics . Neurology 58 : 1418 – 1422 85 . Arabia G , Zappia M , Bosco D et al ( 2002 ) Body weight , levo - dopa pharmacokinetics and dyskinesia in Parkinson’s disease . Neurol Sci 23 : S53 – S54 86 . Kumagai T , Nagayama H , Ota T , Nishiyama Y , Mishina M , Ueda M ( 2014 ) Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease . Clin Neu - ropharmacol 37 : 173 – 176 87 . Martinelli P , Contin M , Scaglione C , Riva R , Albani F , Baruzzi A ( 2003 ) Levodopa pharmacokinetics and dyskinesias : are there sex - related differences ? Neurol Sci 24 : 192 – 193 88 . Martinez - Ramirez D , Giugni J , Vedam - Mai V et al ( 2014 ) The ‘‘brittle response’’ to Parkinson’s disease medications : charac - terization and response to deep brain stimulation . PLoS One 9 : e94856 89 . Montaurier C , Morio B , Bannier S , Derost P et al ( 2007 ) Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation . Brain 130 : 1808 – 1818 90 . Kleiner - Fisman G , Herzog J , Fisman DN et al ( 2006 ) Subtha - lamic nucleus deep brain stimulation : summary and meta - anal - ysis of outcomes . Mov Disord 14 : S290 – S304 91 . Chan AK , McGovern RA , Brown LT et al ( 2014 ) Disparities in access to deep brain stimulation surgery for Parkinson disease : interaction between African American race and Medicaid use . JAMA Neurol 71 : 291 – 299 92 . Willis AW , Schootman M , Kung N , Wang XY , Perlmutter JS , Racette BA ( 2014 ) Disparities in deep brain stimulation surgery among insured elders with Parkinson disease . Neurology 82 : 163 – 171 93 . Hariz GM , Nakajima T , Limousin P et al ( 2011 ) Gender dis - tribution of patients with Parkinson’s disease treated with sub - thalamic deep brain stimulation ; a review of the 2000 - 2009 literature . Parkinsonism Relat Disord 17 : 146 – 149 94 . Hamberg K , Hariz GM ( 2014 ) The decision - making process leading to deep brain stimulation in men and women with parkinson’s disease—an interview study . BMC Neurol 14 : 89 95 . Hariz GM , Lindberg M , Hariz MI , Bergenheim AT ( 2003 ) Gender differences in disability and health - related quality of life in patients with Parkinson’s disease treated with stereotactic surgery . Acta Neurol Scand 108 : 28 – 37 96 . Chandran S , Krishnan S , Rao RM , Sarma SG , Sarma PS , Kishore A ( 2014 ) Gender inﬂuence on selection and outcome of deep brain stimulation for Parkinson’s disease . Ann Indian Acad Neurol 17 : 66 – 70 97 . Hariz GM , Limousin P , Zrinzo L et al ( 2013 ) Gender differences in quality of life following subthalamic stimulation for Parkin - son’s disease . Acta Neurol Scand 128 : 281 – 285 98 . Chiou SM ( 2015 ) Sex - related prognostic predictors for Parkin - son disease undergoing subthalamic stimulation . World Neuro - surg 84 : 906 – 912 99 . Accolla E , Caputo E , Cogiaamanian F et al ( 2007 ) Gender differences in patients with Parkinson’s disease treated with subthalamic deep brain stimulation . Mov Disord 22 : 1150 – 1156 100 . Romito LM , Contarino FM , Albanese A ( 2010 ) Transient gen - der - related effects in Parkinson’s disease patients with subtha - lamic stimulation . J Neurol 257 : 603 – 608 1606 J Neurol ( 2017 ) 264 : 1583 – 1607 123 101 . Scelzo E , Mehrkens JH , Bo¨tzel K , Krack P et al ( 2015 ) Deep brain stimulation during pregnancy and delivery : experience from a series of ‘‘DBS Babies’’ . Front Neurol 6 : 191 102 . Smith KM , Dahodwala N ( 2014 ) Sex differences in Parkinson’s disease and other movement disorders . Exp Neurol 259 : 44 – 56 103 . Gillies GE , Pienaar IS , Vohra S , Qamhawi Z ( 2014 ) Sex dif - ferences in Parkinson’s disease . Front Neuroendocrinol 35 : 370 – 384 104 . Litim N , Morissette M , Di Paolo T ( 2016 ) Neuroactive gonadal drugs for neuroprotection in male and female models of Parkinson’s disease . Neurosci Biobehav Rev 67 : 79 – 88 105 . Benedetti MD , Maraganore DM , Bower JH et al ( 2001 ) Hys - terectomy , menopause , and estrogen use preceding Parkinson’s disease : an exploratory case - control study . Mov Disord 16 : 830 – 837 106 . Martignoni E , Nappi RE , Citterio A et al ( 2002 ) Parkinson’s disease and reproductive life events . Neurol Sci 23 : S85 – S86 107 . Currie LJ , Harrison MB , Trugman JM , Bennett JP , Wooten GF ( 2004 ) Postmenopausal estrogen use affects risk for Parkinson disease . Arch Neurol 61 : 886 – 888 108 . Ragonese P , D’Amelio M , Salemi G et al ( 2004 ) Risk of Parkinson disease in women : effect of reproductive character - istics . Neurology 62 : 2010 – 2014 109 . Popat RA , Van Den Eeden SK , Tanner CM et al ( 2005 ) Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease . Neurology 65 : 383 – 390 110 . Ascherio A , Chen H , Schwarzschild MA , Zhang SM , Colditz GA , Speizer FE ( 2003 ) Caffeine , postmenopausal estrogen , and risk of Parkinson’s disease . Neurology 60 : 790 – 795 111 . Rocca WA , Bower JH , Maraganore DM et al ( 2008 ) Increased risk of parkinsonism in women who underwent oophorectomy before menopause . Neurology 70 : 200 – 209 112 . Simon KC , Chen H , Gao X , Schwarzschild MA , Ascherio A ( 2009 ) Reproductive factors , exogenous estrogen use , and risk of Parkinson’s disease . Mov Disord 24 : 1359 – 1365 113 . Nicoletti A , Nicoletti G , Arabia G et al ( 2011 ) Reproductive factors and Parkinson’s disease : a multicenter case - control study . Mov Disord 26 : 2563 – 2566 114 . Frigerio R , Breteler MM , de Lau LM et al ( 2007 ) Number of children and risk of Parkinson’s disease . Mov Disord 22 : 632 – 639 115 . Rugbjerg K , Christensen J , Tjonneland A , Olsen JH ( 2013 ) Exposure to estrogen and women’s risk for Parkinson’s disease : a prospective cohort study in Denmark . Parkinsonism Relat Disord 19 : 457 – 460 116 . Marder K , Tang MX , Alfaro B et al ( 1998 ) Postmenopausal estrogen use and Parkinson’s disease with and without dementia . Neurology 50 : 1141 – 1143 117 . Greene N , Lassen CF , Rugbjerg K , Ritz B ( 2014 ) Reproductive factors and Parkinson’s disease risk in Danish women . Eur J Neurol 21 : 1168 – 1177 118 . Liu R , Baird D , Park Y , Freedman ND et al ( 2014 ) Female reproductive factors , menopausal hormone use , and Parkinson’s disease . Mov Disord 29 : 889 – 896 119 . Gatto NM , Deapen D , Stoyanoff S et al ( 2014 ) Lifetime expo - sure to estrogens and Parkinson’s disease in California teachers . Parkinsonism Relat Disord 20 : 1149 – 1156 120 . Gardiner SA , Morrison MF , Mozley PD et al ( 2004 ) Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy , postmenopausal women . Am J Geriatr Psychiatry 12 : 621 – 630 121 . Tsang K , Ho S , Lo S ( 2000 ) Estrogen improves motor disability in parkinsonian postmenopausal women with motor ﬂuctuations . Neurology 54 : 2292 – 2298 122 . Blanchet PJ , Fang J , Hyland K , Arnold LA , Mouradian MM , Chase TN ( 1999 ) Short - term effects of high - dose 17beta - estra - diol in postmenopausal PD patients : a crossover study . Neu - rology 53 : 91 – 95 123 . Parkinson Study Group POETRY Investigators ( 2011 ) A ran - domized pilot trial of estrogen replacement therapy in post - menopausal women with Parkinson’s disease . Parkinsonism Relat Disord 17 : 757 – 760 124 . Nicoletti A et al ( 2007 ) Hormonal replacement therapy in women with Parkinson disease and levodopa - induced dyskine - sia : a crossover trial . Clin Neuropharmacol 30 : 276 – 280 125 . Strijks E , Kremer JA , Horstink MW ( 1999 ) Effects of female sex steroids on Parkinson’s disease in postmenopausal women . Clin Neuropharmacol 22 : 93 – 97 126 . Voskuhl RR , Wang H , Wu TC et al ( 2016 ) Estriol combined with glatiramer acetate for women with relapsing - remitting multiple sclerosis : a randomised , placebo - controlled , phase 2 trial . Lancet Neurol 15 : 35 – 46 127 . Rossouw JE , Anderson GL , Prentice RL et al ( 2002 ) Risks and beneﬁts of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial . JAMA 288 : 321 – 333 128 . Picillo M , Fasano A ( 2015 ) How much does sex matter in Parkinson disease ? Neurology 84 : 2102 – 2104 129 . Augustine EF , Pe´rez A , Dhall R et al ( 2015 ) Sex differences in clinical features of early , treated Parkinson’s disease . PLoS One 10 : e0133002 130 . Fengler S , Roeske S , Heber I et al ( 2016 ) Verbal memory declines more in female patients with Parkinson’s disease : the importance of gender - corrected normative data . Psychol Med 46 : 2275 – 2286 131 . Gao L , Nie K , Tang H et al ( 2015 ) Sex differences in cognition among Chinese people with Parkinson’s disease . J Clin Neurosci 22 : 488 – 492 132 . Scott B , Borgman A , Engler H , Johnels B , Aquilonius SM ( 2000 ) Gender differences in Parkinson’s disease symptom proﬁle . Acta Neurol Scand 102 : 37 – 43 133 . Wee N , Kandiah N , Acharyya S , Chander RJ , Ng A , Au WL , Tan LC ( 2016 ) Baseline predictors of worsening apathy in Parkinson’s disease : a prospective longitudinal study . Parkin - sonism Relat Disord 23 : 95 – 98 134 . Jain S , Ton TG , Boudreau RM et al ( 2011 ) The risk of Parkinson disease associated with urate in a community - based cohort of older adults . Neuroepidemiology 36 : 223 – 229 135 . Lyons KE , Hubble JP , Tro¨ster AI , Pahwa R , Koller WC ( 1998 ) Gender differences in Parkinson’s disease . Clin Neuropharmacol 21 : 118 – 121 J Neurol ( 2017 ) 264 : 1583 – 1607 1607 123